Bavdegalutamide for treating prostate cancer without ar l702h mutation

Bavdegalutamide targets and degrades the androgen receptor, overcoming resistance from AR L702H mutations in prostate cancer, enhancing treatment efficacy by selectively targeting AR proteins and improving patient outcomes.

WO2024233696A1PCT designated stage expired Publication Date: 2024-11-14ARVINAS OPERATIONS INC

Patent Information

Application Number
PCT/US2024/028421
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-27
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for prostate cancer, particularly those targeting the androgen receptor (AR), face challenges due to resistance from AR tumor mutations like AR L702H, which hinder effective treatment outcomes, especially in patients with advanced androgen-independent tumors.

Method used

Bavdegalutamide (Compound A), a PROteolysis TArgeting Chimera (PROTAC) bifunctional compound, specifically targets the androgen receptor for degradation via the ubiquitin-proteasome system, effectively degrading wild-type AR and clinically relevant mutants except for the AR L702H mutation, thereby offering a targeted therapeutic approach.

Benefits of technology

Compound A demonstrates clinical activity in treating prostate cancer by selectively degrading AR proteins, including resistant mutants, leading to improved overall survival and PSA declines in patients without the AR L702H mutation, providing a therapeutic benefit by modulating protein levels and inhibiting AR activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028421_14112024_PF_FP_ABST
    Figure US2024028421_14112024_PF_FP_ABST
Patent Text Reader

Abstract

This disclosure pertains to methods of treating prostate cancer in a subject with one or more mutations in the Androgen Receptor ligand binding domain, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naïve to novel hormonal agents (NHAs), metastatic prostate cancer naïve NHAs, castrate-resistant prostate cancer naïve to NHAs, castrate-sensitive prostate cancer naïve to NHAs, metastatic castrate-resistant prostate cancer naïve to NHAs, and metastatic castrate-sensitive prostate cancer naïve to NHAs, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

BAVDEGALUTAMID FOR TREATING PROSTATECANCER WITHOUT AR L702H MUTATIONRELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of U.S. Provisional Application No. 63 / 501,138, filed May 9, 2023, U.S. Provisional Application No. 63 / 508,725, filed June 16, 2023, U.S. Provisional Application No. 63 / 589,930, filed October 12, 2023, U.S. Provisional Application No. 63 / 592,175, filed October 21, 2023, and U.S. Provisional Application No. 63 / 593,725, filed October 27, 2023, the contents of each of which are incorporated herein by reference in their entirety for all purposes.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (ARVN_047_001WO_SeqList_ST26.xml; Size: 2,675 bytes; and Date of Creation: March 8, 2024) are herein incorporated by reference in their entireties.FIELD OF THE DISCLOSURE

[0003] This application relates to treating prostate cancer, including adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), comprising administering Compound A to a subject in need of treatment.BACKGROUND OF THE DISCLOSURE

[0004] Androgen Receptor (AR) belongs to a nuclear hormone receptor family that is activated by androgens, such as testosterone and dihydrotestosterone (Pharmacol. Rev. 2006, 58(4), 782-97; Vitam. Horn. 1999, 55:309-52.). In the absence of androgens, AR is bound by Heat Shock Protein90 (Hsp90) in the cytosol. When an androgen binds AR, its conformation changes to release AR from Hsp90 and to expose the Nuclear Localization Signal (NLS). The latter enables AR to translocate into the nucleus where AR acts as a transcription factor to promote gene expression responsible for male sexual characteristics (Endocr. Rev. 1987, 8(1): 1-28; Mol. Endocrinol. 2002, 16(10), 2181-7). AR deficiency leads to Androgen Insensitivity Syndrome, formerly termed testicular feminization.

[0005] While AR is responsible for development of male sexual characteristics, it is also a well-documented oncogene in certain forms of cancers including prostate cancers (Endocr. Rev. 2004, 25(2), 276-308). A commonly measured target gene of AR activity is the secreted Prostate Specific Antigen (PSA) protein. The current treatment regimen for prostate cancer involves inhibiting the androgen-AR axis by two methods. The first approach relies on reduction of androgens, while the second strategy aims to inhibit AR function (Nat. Rev. Drug Discovery, 2013, 12, 823-824). Despite the development of effective targeted therapies, most patients develop resistance and the disease progresses. An alternative approach for the treatment of prostate cancer involves eliminating the AR protein. Because AR is a critical driver of tumorigenesis in many forms of prostate cancers, its elimination should lead to a therapeutically beneficial response. There exists an ongoing need in the art for effective treatments for diseases, especially cancer and prostate cancer. However, non-specific effects, and the inability to target and modulate certain classes of proteins altogether, such as transcription factors, remain as obstacles to the development of effective anti-cancer agents. As such, small molecule therapeutic agents that leverage or potentiate cereblon's substrate specificity and, at the same time, are "tunable" such that a wide range of protein classes can be targeted and modulated with specificity would be very useful as a therapeutic.

[0006] Over 70 different somatic missense AR tumor mutation have been identified in patients with prostate cancer (Gottlieb, B., Hum. Mutat. 2004, 23: 527-533). The majority of these AR tumor mutations reside in the ligand binding domain. Without being bound by theory, AR tumor mutations in the ligand binding domain result in decreased ligand specificity, thereby enabling AR to function independently of androgen. Such AR tumor mutations provide tumor cells with the capability to proliferate in androgen- depleted environments, and thus are selected for in response to therapies for prostate cancer that block or reduce androgen levels (e.g., luteinizing hormone- rel easing hormone agonists). Accordingly, AR tumor mutations are observed with increasedfrequency in patients having advanced, androgen-independent tumors as compared to patients having early-stage prostate cancer (Taplin, M.E., et al. N. Engl. J. Med. (1995) 332: 1393-1398; Marcelli, M., et al. Cancer Res. (2000) 60: 944-949).

[0007] Bavdegalutamide, i.e. N-[(lr,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4- [2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-lH-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]pyridazine-3-carboxamide, and referred to herein as “Compound A” or “Cpd A”, is a PROteolysis TArgeting Chimera (PROTAC®) bifunctional compound that targets the androgen receptor (AR) protein for degradation via the ubiquitin-proteasome system, and has the following structure:

[0008] Patients with mCRPC and mutations in AR LBD (Androgen Receptor ligand binding domain, i.e.: amino acids 671-920) have poor prognosis. In matched real-world cohorts of patients with mCRPC, those with the AR LBD mutations T878 and / or H875 had significantly shorter real- world overall survival from first-line treatment initiation than those without these mutations (median: 16.1 months [95% CI: 11.4-26.8] vs 50.7 months [95% CI: 45.4-59.8]; P0.0001) (Stewart, T. F. et al. Presented at ESMO; Sep 9-13, 2022; Paris, France. Poster 1407P).

[0009] Compound A showed clinical activity in previously treated patients with mCRPC in a phase 1 / 2 study (Clinical Trial Registration: NCT03888612, incorporated by reference herein in its entirety for all purposes), with enhanced activity seen in patients with the AR LBD mutations T878 and / or H875.SUMMARY

[0010] In one aspect, this application pertains to a method of treating prostate cancer in a subject, comprising administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the subject does not have an AR L702H mutation.

[0011] In one aspect, this application pertains to a method of selecting a subject for treatment of prostate cancer, comprising:(i) determining the subject’s AR mutation status; and(ii) administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof only if the subject does not have an AR L702H mutation.

[0012] In one aspect, this application pertains to a method of treating prostate cancer in a subject, comprising administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein if the subject has an AR L702H mutation the subject is not administered Compound A, or a pharmaceutically acceptable salt thereof.

[0013] In one aspect, this application pertains to a method of treating prostate cancer in a subject, comprising administering Compound A:the subject in need thereof, wherein the subject does not have an AR L702H mutation.

[0014] In one aspect, this application pertains to a method of selecting a subject for treatment of prostate cancer, comprising:(i) determining the subject’s AR mutation status; and(ii) administering Compound A:the subject in need thereof only if the subject does not have an AR L702H mutation.

[0015] In one aspect, this application pertains to a method of treating prostate cancer in a subject, comprising administering Compound A:the subject in need thereof, wherein if the subject has an AR L702H mutation the subject is not administered Compound A.

[0016] In some embodiments, the prostate cancer is metastatic prostate cancer.

[0017] In some embodiments, the prostate cancer is castrate-resistant prostate cancer.

[0018] In some embodiments, the prostate cancer is metastatic castrate-resistant prostate cancer.

[0019] In some embodiments, the prostate cancer is castrate-sensitive prostate cancer.

[0020] In some embodiments, the prostate cancer is metastatic castrate-sensitive prostate cancer.

[0021] In some embodiments, the prostate cancer is prostate cancer naive to novel hormonal agents (NHA).

[0022] In some embodiments, the prostate cancer is castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

[0023] In some embodiments, the prostate cancer is castrate-resistant prostate cancer naive to novel hormonal agents (NHA).

[0024] In some embodiments, the prostate cancer is metastatic prostate cancer naive to novel hormonal agents (NHA).

[0025] In some embodiments, the prostate cancer is metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA).

[0026] In some embodiments, the prostate cancer is metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

[0027] In some embodiments, the subject has any ARLBD mutation except L702H.

[0028] In some embodiments, the subject has any AR LBD mutation other than T878X andL702H.

[0029] In some embodiments, the subject has any AR LBD mutation other than H875X and L702H.

[0030] In some embodiments, the subject has any AR LBD mutation other than T878X, H875X, and L702H.

[0031] In some embodiments, the subject has an AR missense mutation between codons 677- 920, without an AR L702H mutation.

[0032] In some embodiments, the subject has an AR T878X mutation without an AR L702H mutation.

[0033] In some embodiments, the subject has an AR H875X mutation without an AR L702H mutation.

[0034] In some embodiments, the subject has both an AR T878X and a H875X mutation without an AR L702H mutation.

[0035] In some embodiments, the subject is administered Compound A once daily.

[0036] In some embodiments, the subject is administered 400 mg Compound A once daily.

[0037] In some embodiments, the subject is administered 420 mg Compound A once daily.BRIEF DESCRIPTION OF THE DRAWINGS

[0038] FIG. 1 A shows the degradation of AR (androgen receptor) but not GR (glucocorticoid receptor) at 30 nM, 100 nM, or 300 nM Compound A in MCF-7 cells.

[0039] FIG. IB shows the selective degradation of AR among nearly 4000 proteins measured mass spectrometry following treatment of VCaP cells with Compound A at 10 nM for 8 hours.

[0040] FIG. 1 C shows Compound A-induced degradation of stably expressed wild-type (WT) AR and clinically relevant mutants of AR, except for L702H, in T-RexTM-293 cells.

[0041] FIG. ID shows Compound A-induced degradation of stably expressed wild-type AR and AR L702H in HEK293 cells and endogenously expressed AR T878A / L702H in MDA PCa 2B cells.

[0042] FIG. IE shows Compound A-induced degradation of stably expressed wild-type (WT) AR and clinically relevant mutants of AR.

[0043] FIG. 2 shows the median radiographic progression-free survival (rPFS) in AR LBD patients and AR 878 / 875 patients administered Compound A 420 mg QD.

[0044] FIG. 3 shows the best PSA declines in AR LBD patients and AR 878 / 875 patients administered Compound A 420 mg QD.

[0045] FIG. 4 shows the duration of treatment of Compound A 420 mg QD in AR LBD patients and AR 878 / 875 patients.

[0046] FIG. 5 shows the best PSA declines in patients having an AR 878 / 875 mutation with or without a co-occurring L702H mutation.

[0047] FIG. 6A shows degradation of wild-type AR and AR L702H, V716M, and W742C mutants by Compound A.

[0048] FIG. 6B shows degradation of wild-type AR and AR L702H, S889G, and T878S mutants by Compound A.

[0049] FIG. 6C shows degradation of wild-type AR and AR W742L and H875Y / T878A mutants by Compound A.

[0050] FIG. 6D shows degradation of wild-type AR and AR L702H, M750T, T878A / D891H, and T878A / S889G mutants by Compound A.

[0051] FIG. 6E shows degradation of wild-type AR and AR L702H, F877L / T878A, and M750V mutants by Compound A.

[0052] FIG. 6F and 6G shows degradation of wild-type AR and the AR D891H mutant by Compound A by Western blot (FIG. 6F) and dose-response curve (FIG. 6G).

[0053] FIG. 7A shows activation of wild-type AR and FIG. 7B shows activation of an AR L702H mutant by steroids in HEK-293 ARE-luciferase reporter cells.

[0054] FIG. 8A shows that Compound A, enzalutamide, and darolutamide inhibited the activation of wild-type AR by 0.1 nM R1881. FIG. 8B shows that Compound A inhibited the activation of AR L702H by 1 nM R1881 more potently than enzalutamide or darolutamide. FIG. 8C-8G show the, that Compound A inhibited the activation of AR L702H by 100 nM prednisolone (FIG. 8C), 500 nM prednisolone (FIG. 8D), 100 nM cortisol (FIG. 8E), 500 nM cortisol (FIG. 8F), and 100 nM cortisone (FIG. 8G) more potently than enzalutamide or darolutamide.

[0055] FIG. 9 shows degradation of the wild-type AR and AR L702H by Compound A in HEK-293 ARE-luciferase reporter cells.

[0056] FIG. 10 shows proliferation of MDA PCa 2B cells after incubation with R1881, cortisol, cortisone, prednisolone, or dexamethasone.

[0057] FIGs. 11A-11C show that Compound A, enzalutamide, and darolutamide inhibit the proliferation of MDA PCA 2B cells when stimulated with 1 nM R1881 (FIG. 11 A), 100 nM cortisol (FIG. 1 IB), and 100 nM cortisone (FIG. 11C).

[0058] FIG. 12 shows that Compound A induced degradation of endogenous mutant AR T878A / L702H in MDA PCa 2B cells.SEQUENCE LISTING

[0059] All references to amino acid mutations in the Androgen Receptor are numbered relative to SEQ ID NO: 1, which is provided below:1 mevqlglgrv yprppsktyr gafqnlfqsv reviqnpgpr hpeaasaapp gasllllqqq61 qqqqqqqqqq qqqqqqqqqq etsprqqqqq qgedgspqah rrgptgylvl deeqqpsqpq 121 salechperg cvpepgaava askglpqqlp appdeddsaa pstlsllgpt fpglsscsad 181 Ikdilseast mqllqqqqqe avsegsssgr areasgapts skdnylggts tisdnakelc 241 kavsvsmglg vealehlspg eqlrgdcmya pllgvppavr ptpcaplaec kgsllddsag 301 kstedtaeys pfkggytkgl egeslgcsgs aaagssgtle Ipstlslyks galdeaaayq 361 srdyynfpla lagppppppp phpharikle npldygsawa aaaaqcrygd laslhgagaa 421 gpgsgspsaa assswhtlft aeegqlygpc gggggggggg gggggggggg gggeagavap481 ygytrppqgl agqesdftap dvwypggmvs rvpypsptcv ksemgpwmds ysgpygdmrl 541 etardhvlpi dyyfppqktc licgdeasgc hygaltcgsc kvffkraaeg kqkylcasrn 601 dctidkfrrk ncpscrlrkc yeagmtlgar klkklgnlkl qeegeasstt spteettqkl 661 tvshiegyec qpiflnvlea iepgwcagh dnnqpdsfaa llsslnelge rqlvhwkwa 721 kalpgfrnlh vddqmaviqy swmglmvfam gwrsftnvns rmlyfapdlv fneyrmhksr 781 mysqcvrmrh Isqefgwlqi tpqeflcmka lllfsiipvd glknqkffde Irmnyikeld 841 riiackrknp tscsrrfyql tklldsvqpi arelhqftfd llikshmvsv dfpemmaeii901 svqvpkilsg kvkpiyfhtq

[0060] As understood by the skilled artisan, AR has a modular structure comprising three functional domains: the N-terminal transcriptional regulation domain, the DNA-binding domain, and the ligand binding domain (MacLean HE, et al J. Steroid Biochem Mol Biol. (1997) 62:233- 42). The DNA-binding domain is linked to the ligand-binding domain via a hinge. The AR ligand binding domain refers to the functional domain of human AR that folds to form a hydrophobic pocket that binds to the AR cognate hormone ligand (e.g., androgen).

[0061] Moreover, it is understood in the art that AR is 920 amino acid residues in length, wherein the N-terminal transcriptional regulation domain extends from amino acid residue 1 to about amino acid residue 559, the DNA-binding domain extends from about amino acid residue 560 to about amino acid residue 624, the hinge extends from about amino acid residue 625 to about amino acid residue 676, and the ligand binding domain extends from about amino acid residue 677 to about amino acid residue 920. A suitable AR reference sequence is set forth by SEQ ID NO: 1 and identified in the UniProt database as Pl 0275 (ANDR_HUMAN). The gene encoding AR (“the AR gene”) is approximately 90kb and has chromosomal coordinates 67544021-67730619 according to human reference genome GRCh38.pl3. The AR gene contains 8 exons, with exon 1 encoding the N-terminal transcriptional regulation domain; exon 2-3 encoding the DNA-binding domain; and exons 4-8 encoding the hinge and ligand binding domain (Jenster, et al (1992) J. Steroid Biochem. Mol. Biol. 41:671-75).DETAILED DESCRIPTIONDEFINITIONS

[0062] All references to amino acid mutations in the Androgen Receptor are numbered relative to SEQ ID NO: 1, which is provided herewith.

[0063] The term “Ubiquitin Ligase” refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, cereblon is an E3 Ubiquitin Ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.

[0064] Compound A, i.e., bavdegalutamide, or N-[(lr,4r)-4-(3-chloro-4- cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3- dihydro-lH-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridazine-3-carboxamide, has the following structure:In some embodiments, Compound A can be prepared as described in U.S. Patent No. 10,584,101 or U.S. Patent Application Publication No. 2023 / 0012321, both of which are incorporated by reference in their entireties.

[0065] “Pharmaceutically acceptable salt”, as used herein, means a salt form of Compound A as well as hydrates of the salt form with one or more water molecules present. Such salt andhydrated forms retain the biological activity of the compound of the disclosure and are not biologically or otherwise undesirable, i.e., exhibit minimal, if any, toxicological effects. Representative "pharmaceutically acceptable salts" include, e.g., water-soluble and waterinsoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N- methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (l,l-methene-bis-2-hydroxy-3 -naphthoate, einbonate), pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

[0066] As used herein, “treating” describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes decreasing or alleviating the symptoms or complications, or eliminating the disease, condition or disorder.

[0067] The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, or inhibiting the progress of the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of "treating" as defined immediately above. For example, the terms "treat", "treating" and "treatment" can refer to a method of alleviating or abrogating a particular disorder and / or one or more of its attendant symptoms.

[0068] As used herein, “subject” means a human or animal (in the case of an animal, the subject can be a mammal). In one aspect, the subject is a human. In one aspect, the subject is a male.

[0069] Prostate cancer is the uncontrolled growth of cancerous cells in the prostate gland. In some embodiments, the prostate cancer is metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA),castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

[0070] Metastatic prostate cancer, or metastases, refers to prostate cancer that has spread beyond the prostate to other parts of the body, e.g., bones, lymph nodes, liver, lungs, brain.

[0071] Castrate-resistant prostate cancer or castration-resistant prostate cancer (or prostate cancer that is castrate- or castration-resistant) is a type of prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels.

[0072] Metastatic castrate-resistant prostate cancer is a type of prostate cancer that has metastasized and continues to grow even when the amount of testosterone in the body is reduced to very low levels.

[0073] Castrate-sensitive prostate cancer or castration-sensitive prostate cancer (CSPC), or prostate cancer that is castrate- or castration-sensitive, is prostate cancer that can be controlled by reducing the amount of androgens (male hormones) in the body (e.g., through castration) and / or prostate cancer that requires androgens to grow and stops growing when androgens are not present. CSPC is also referred to as androgen-dependent prostate cancer, androgen-sensitive prostate cancer, or hormone-sensitive prostate cancer (HSPC).

[0074] Metastatic castrate-sensitive prostate cancer is a type of castrate-sensitive prostate cancer that has metastasized and requires androgens to grow or can be controlled by reducing the amount of androgens in the body (e.g., through castration).

[0075] Prostate cancer naive to novel hormonal agents (NHA) is prostate cancer that has not been previously treated with second-generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone or abiraterone acetate. In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0076] Metastatic prostate cancer naive to novel hormonal agents (NHA) is metastatic prostate cancer that has not been previously treated with second-generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, theandrogen biosynthesis inhibitor is abiraterone or abiraterone acetate. In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0077] Castrate-resistant prostate cancer naive to novel hormonal agents (NHA) is castrateresistant prostate cancer that has not been previously treated with second-generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone or abiraterone acetate. In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0078] Castrate-sensitive prostate cancer naive to novel hormonal agents (NHA) is castratesensitive prostate cancer that has not been previously treated with second-generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone or abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0079] Metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA) is metastatic castrate-resistant prostate cancer that has not been previously treated with second- generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone or abiraterone acetate. In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0080] Metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA) is metastatic castrate-sensitive prostate cancer that has not been previously treated with second- generation antiandrogens such as androgen biosynthesis inhibitors or androgen receptor blockers. In some embodiments, the androgen biosynthesis inhibitor is abiraterone or abiraterone acetate). In some embodiments, the androgen receptor blocker is enzalutamide, darolutamide, or apalutamide.

[0081] As used herein, “preventing” describes stopping the onset of the symptoms or complications of the disease, condition or disorder.

[0082] ‘Administration” refers to introducing an agent, such as a compound of the disclosure into a subject. The related terms “administering” and “administration of’ (and grammatical equivalents) refer both to direct administration, which may be administration to a subject by a medical professional or by self-administration by the subject, and / or to indirect administration, which may be the act of prescribing a drug. For example, a physician who instructs a patient toself-administer a drug and / or provides a patient with a prescription for a drug is administering the drug to the patient.

[0083] The terms "co-administration" and "co-administering" or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, Compound A is co-administered in combination with at least one additional bioactive agent, especially including an anti-cancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and / or therapy, including anticancer activity.

[0084] "Therapeutically effective amount", as used herein means an amount of the free base of Compound A, or the equivalent amount of a pharmaceutically acceptable salt of Compound A, that is sufficient to treat, ameliorate, or prevent a specified disease (e.g., prostate cancer), disease symptom, disorder or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The effective amount for a particular subject may depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and whether additional therapeutics are to be administered to the subject. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.

[0085] Cm ax ’, as used herein, refers to the observed maximum (peak) plasma concentration of a specified compound in the subject after administration of a dose of that compound to the subject.

[0086] ‘AUC”, as used herein, refers to the total area under the plasma concentration-time curve, which is a measure of exposure to a compound of interest, and is the integral of the concentration- time curve after a single dose or at steady state. AUC is expressed in units of ng*H / mL (ng x H / mL), where “H” refers to hours.

[0087] ‘AUCtau”, as used herein, refers to the AUC from 0 hours to the end of a dosing interval.

[0088] ‘AUC0-24” means the AUC from 0 hours to 24 hours after administration of a single dose.

[0089] “Comprising” or “comprises” as applied to a particular dosage form, composition, use, method or process described or claimed herein means that the dosage form, composition, use, method, or process includes all of the recited elements in a specific description or claim but does not exclude other elements. “Consists essentially of’ and “consisting essentially of’ means that the described or claimed composition, dosage form, method, use, or process does not exclude other materials or steps that do not materially affect the recited physical, pharmacological, pharmacokinetic properties or therapeutic effects of the composition, dosage form, method, use, or process. “Consists of’ and “consisting of’ means the exclusion of more than trace elements of other ingredients and substantial method or process steps

[0090] The term “about” as part of a quantitative expression such as “about X”, includes any value that is 10% higher or lower than X, and also includes any numerical value that falls between X-10% and X+10%. Thus, for example, a weight of about 40 g includes a weight of between 36 to 44 g. When used herein to denote amino acid residues in the AR, the term “about” means any amino acid residue that is within 5 amino acid residues of what is specified. For example, when referring to a contiguous stretch of amino acid residues extending from about amino acid residue 560 to about amino acid residue 624 of the AR, this refers to a contiguous stretch of amino acid residues extending from amino acid residue 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, or 565, to ammo acid residue 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, or 629 of the AR of SEQ ID NO: 1. In some embodiments, the term “about” means any amino acid residue that is within 3 amino acid residues of what is specified. In some embodiments, the term “about” means any amino acid residue that is within 1 amino acid residue of what is specified.

[0091] The ECOG Scale of Performance Status was developed by the Eastern Cooperative Oncology Group as standard criteria for measuring how the disease impacts a patient’s daily living abilities. It describes a patient’s level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). Patients are categorized on a scale of 1-5:GRADE ECOG PERFORMANCE STATUS0 Fully active, able to carry on all pre-disease performance without restrictionRestricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hoursCapable of only limited selfcare; confined to bed or chair more than 50% of waking hours4 Completely disabled; cannot carry on any selfcare; totally confined to bed or chair5 Dead

[0092] ‘Fasted condition” or “fasted state” as used to describe a subject means the subject has not eaten for at least 4 hours before a time point of interest, such as the time of administering a compound of the disclosure (preferably Compound A or a pharmaceutically acceptable salt thereof). In an embodiment, a subject in the fasted state has not eaten for at least any of 6, 8, 10 or 12 hours prior to administration of a compound of the disclosure (preferably Compound A or a pharmaceutically acceptable salt thereof).

[0093] ‘Fed condition” or “fed state” as used to describe a subject herein means the subject has eaten less than 4 hours before a time point of interest, such as the time of administering a compound of the disclosure (preferably Compound A or a pharmaceutically acceptable salt thereof). In an embodiment, a subject in the fed state has eaten within at least any of 3, 2, 1 or 0.5 hours prior to administration of a compound of the disclosure (preferably Compound A or a pharmaceutically acceptable salt thereof).

[0094] The articles "a" and "an" are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0095] The term "and / or" is used in this disclosure to mean either "and" or "or" unless indicated otherwise.

[0096] The terms "patient" and “subject” are used interchangeably herein, and refer to a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.

[0097] In some embodiments, the subject is a human.

[0098] In some embodiments, the subject is a human who has been diagnosed with prostate cancer.

[0099] In some embodiments, the subject is a human who has been diagnosed with metastatic prostate cancer.

[0100] In some embodiments, the subject is a human who has been diagnosed with castrateresistant prostate cancer.

[0101] In some embodiments, the subject is a human who has been diagnosed with metastatic castrate-resistant prostate cancer.

[0102] In some embodiments, the subject is a human who has been diagnosed with castratesensitive prostate cancer.

[0103] In some embodiments, the subject is a human who has been diagnosed with metastatic castrate-sensitive prostate cancer.

[0104] In some embodiments, the subject is a human who has been diagnosed with prostate cancer naive to novel hormonal agents (NHA).

[0105] In some embodiments, the subject is a human who has been diagnosed with castratesensitive prostate cancer naive to novel hormonal agents (NHA).

[0106] In some embodiments, the subject is a human who has been diagnosed with castrateresistant prostate cancer naive to novel hormonal agents (NHA)

[0107] In some embodiments, the subject is a human who has been diagnosed with metastatic prostate cancer naive to novel hormonal agents (NHA).

[0108] In some embodiments, the subject is a human who has been diagnosed with metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA).

[0109] In some embodiments, the subject is a human who has been diagnosed with metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).METHODS OF UBIQUITINATING / DEGRADING A TARGET PROTEIN IN A CELL

[0110] The present disclosure provides a method of ubiquitinating / degrading a target protein in a cell. The method comprises administering a bifunctional composition comprising an E3 ubiquitin ligase binding moiety and a protein targeting moiety, preferably linked through a linker moiety, as otherwise described herein, wherein the E3 ubiquitin ligase binding moiety is coupled to the protein targeting moiety and wherein the E3 ubiquitin ligase binding moiety recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase) and the protein targeting moiety recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in degradation / inhibition of the effects of the target protein and the control of protein levels. Thecontrol of protein levels afforded by the present disclosure provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.

[0111] In one aspect, this application provides Compound A, or a pharmaceutically acceptable salt thereof, that degrades the androgen receptor (AR) protein. In some embodiments, the AR that is degraded by Compound A is wild type AR. In some embodiments, the AR that is degraded by Compound A is a mutant form of AR.

[0112] As understood by the skilled artisan, AR has a modular structure comprising three functional domains: the N-terminal transcriptional regulation domain, the DNA-binding domain, and the ligand binding domain (MacLean HE, et al J. Steroid Biochem Mol Biol. (1997) 62:233- 42). The DNA-binding domain is linked to the ligand-binding domain via a hinge. The AR ligand binding domain refers to the functional domain of human AR that folds to form a hydrophobic pocket that binds to the AR cognate hormone ligand (e.g., androgen).

[0113] Moreover, it is understood in the art that AR is 920 amino acid residues in length, wherein the N-terminal transcriptional regulation domain extends from amino acid residue 1 to about amino acid residue 559, the DNA-binding domain extends from about amino acid residue 560 to about amino acid residue 624, the hinge extends from about amino acid residue 625 to about amino acid residue 676, and the ligand binding domain extends from about amino acid residue 677 to about amino acid residue 920. A suitable AR reference sequence is set forth by SEQ ID NO: 1 and identified in the UniProt database as Pl 0275 (ANDR_HUMAN). The gene encoding AR (“the AR gene”) is approximately 90kb and has chromosomal coordinates 67544021-67730619 according to human reference genome GRCh38.pl3. The AR gene contains 8 exons, with exon 1 encoding the N-terminal transcriptional regulation domain; exon 2-3 encoding the DNA-binding domain; and exons 4-8 encoding the hinge and ligand binding domain (Jenster, et al (1992) J. Steroid Biochem. Mol. Biol. 41:671-75).

[0114] In some embodiments, the subject has a prostate cancer comprising at least one somatic AR tumor mutation in a functional domain of AR. In some embodiments, the at least one somatic AR tumor mutation is an insertion, deletion, or substitution of one or more amino acid residues in an AR functional domain as compared to an AR reference sequence (e.g., SEQ ID NO: 1). In some embodiments, the at least one somatic AR tumor mutation is a substitution of one or more amino acid residues in an AR functional domain as compared to an AR reference sequence (e.g., SEQ IDNO: 1). In some embodiments, the at least one somatic AR tumor mutation is an insertion, deletion, or substitution of one or more amino acid residues in the AR ligand binding domain as compared to an AR reference sequence (e.g., SEQ ID NO: 1). In some embodiments, the at least one somatic AR tumor mutation is a substitution of one or more amino acid residues in the AR ligand binding domain as compared to an AR reference sequence (e.g., SEQ ID NO: 1). In some embodiments, the at least one somatic AR tumor mutation is an insertion, deletion or substitution of one or more amino acid residues selected from amino acid residues 677-920 as compared to an AR reference sequence, wherein the AR reference sequence is set forth by SEQ ID NO: 1. In some embodiments, the at least one somatic AR tumor mutation is a substitution of one or more amino acid residues selected from amino acid residues 677-920 as compared to an AR reference sequence, wherein the AR reference sequence is set forth by SEQ ID NO: 1.

[0115] In some embodiments, the alteration (e.g., substitution) of an amino acid residue in the AR ligand binding domain provides a mutant AR having reduced ligand specificity and / or enhanced cofactor recruitment. Without being bound by theory, a mutant AR having a reduced ligand specificity and / or enhanced cofactor recruitment has increased potency for triggering the AR signaling pathway, thereby conferring a growth advantage on a tumor cell comprising the mutant AR.

[0116] In some embodiments, the prostate cancer comprises cancer cells characterized by expression of at least one somatic AR tumor mutation described herein. Methods to identify a cancer characterized by expression of somatic mutations are known in the art, and include, e.g., obtaining a biological sample from the subject, harvesting the biological sample to obtain genetic material (e.g., genomic DNA or RNA), and performing sequencing analysis, RNA-sequencing analysis, or real-time polymerase chain reaction (RT-PCR). For example, in some embodiments, genomic DNA is first obtained (using any standard technique) from cancerous tissue obtained from the subject, cDNA is prepared, and amplification is performed (e.g., using a polymerase chain reaction) to provide the cDNA in sufficient quantity for sequence analysis, and sequencing is performed using, e.g., next generation sequencing. Genomic DNA or RNA is typically extracted from biological samples such as tissues removed from the subject, e.g., by tissue biopsy. In some embodiments, the biological sample is a tissue biopsy sample (e.g., a prostate biopsy sample), wherein sequence analysis of genomic DNA or RNA is performed to identify the presence of somatic mutations in AR (e.g., a somatic mutation resulting in a substitution of an amino acidresidue in the AR ligand binding domain). In some embodiments, the biological sample comprises plasma obtained from the subject is used to detect somatic AR tumor mutations present in circulating tumor DNA, e.g., using PCR-based amplification, followed by gene sequencing.

[0117] In some embodiments, the mutant form of AR that is degraded by Compound A or a pharmaceutically acceptable salt thereof, comprises at least one AR somatic tumor mutation.

[0118] In some embodiments, the at least one somatic AR tumor mutation is T878 or T878X, wherein “X” refers to any amino acid residue other than the wild type residue at that position. In some embodiments, the at least one somatic AR tumor mutation is T878X, wherein “X” refers to an amino acid residue, other than the wild type residue at that position, selected from alanine (A); valine (V); leucine (L); isoleucine (I); phenylalanine (F); methionine (M); tryptophan (W); proline (P); glycine (G); serine (S); threonine (T); cysteine (C); asparagine (N); glutamine (Q); tyrosine (Y); lysine (K); arginine (R); histidine (H); aspartate (D); and glutamate (E). In some embodiments, the at least one somatic AR tumor mutation is T878X, wherein “X” refers to an amino acid residue, other than the wild type residue at that position, selected from alanine (A) and serine (S). In some embodiments, the at least one somatic AR tumor mutation is T878A. In some embodiments, the at least one somatic AR tumor mutation is T878S.

[0119] In some embodiments, the at least one somatic AR tumor mutation is H875 or H875X, wherein “X” refers to any amino acid residue other than the wild type residue at that position. In some embodiments, the at least one somatic AR tumor mutation is H875X, wherein “X” refers to an amino acid residue, other than the wild type residue at that position, selected from alanine (A); valine (V); leucine (L); isoleucine (I); phenylalanine (F); methionine (M); tryptophan (W); proline (P); glycine (G); serine (S); threonine (T); cysteine (C); asparagine (N); glutamine (Q); tyrosine (Y); lysine (K); arginine (R); histidine (H); aspartate (D); and glutamate (E). In some embodiments, the at least one somatic AR tumor mutation is H875Y.

[0120] In some embodiments, the at least one somatic AR tumor mutation is not L702 or L702X, wherein “X” refers to any amino acid residue other than the wild type residue at that position. In some embodiments, the at least one somatic AR tumor mutation is not L702X, wherein “X” refers to an amino acid residue, other than the wild type residue at that position, selected from alanine (A); valine (V); leucine (L); isoleucine (I); phenylalanine (F); methionine (M); tryptophan (W); proline (P); glycine (G); serine (S); threonine (T); cysteine (C); asparagine (N); glutamine(Q); tyrosine (Y); lysine (K); arginine (R); histidine (H); aspartate (D); and glutamate (E). In some embodiments, the at least one somatic AR tumor mutation is not L702H.

[0121] In some embodiments, the at least one somatic AR tumor mutation is any AR LBD mutation except L702 or L702X. In some embodiments, the at least one somatic AR tumor mutation is any AR LBD mutation except L702H.

[0122] In some embodiments, the subject comprises at least one AR LBD mutation that is not L702 or L702X. In some embodiments, the subject comprises at least one AR LBD mutation that is not L702H.

[0123] In some embodiments, the mutant form of AR that is degraded by Compound A, or a pharmaceutically acceptable salt thereof, comprises at least two AR somatic tumor mutations.

[0124] In some embodiments, the mutant form of AR that is degraded by the Compound A comprises at least two AR somatic tumor mutations.

[0125] In some embodiments, the mutant form of AR that is degraded by Compound A, or a pharmaceutically acceptable salt thereof, comprises at least two AR somatic tumor mutations, wherein neither mutation is L702H.

[0126] In some embodiments, the mutant form of AR that is degraded by the Compound A comprises at least two AR somatic tumor mutations, wherein neither mutation is L702H.METHODS OE TREATMENT

[0127] In one aspect, the present application pertains to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the disclosure, preferably Compound A, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or isotopic derivative thereof.

[0128] In one aspect, the present application pertains to a method of preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the disclosure, preferably Compound A, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, or isotopic derivative thereof.

[0129] In one aspect, the present application pertains to a method of treating and / or preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or isotopic derivative thereof.

[0130] In one aspect, the present application pertains to a method of treating and / or preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, in combination with one or more additional anti-cancer agents.

[0131] In one aspect, the present application pertains to a method of treating and / or preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.

[0132] In one aspect, the present application pertains to a method of treating and / or preventing cancer comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, in combination with one or more additional anti-cancer agents.

[0133] The methods of treating cancer described herein result in a reduction in tumor size. Alternatively, or in addition, the cancer is metastatic cancer, and this method of treatment includes inhibition of metastatic cancer cell invasion.

[0134] In some embodiments, the cancer is prostate cancer.

[0135] In some embodiments, the cancer is adenocarcinoma of the prostate.

[0136] In some embodiments, the cancer is metastatic prostate cancer.

[0137] In some embodiments, the cancer is castrate-resistant prostate cancer.

[0138] In some embodiments, the cancer is metastatic castrate-resistant prostate cancer (mCRPC).

[0139] In some embodiments, the cancer is progressive mCRPC.

[0140] In some embodiments, the prostate cancer is castrate-sensitive prostate cancer.

[0141] In some embodiments, the prostate cancer is metastatic castrate-sensitive prostate cancer.

[0142] In some embodiments, the prostate cancer is prostate cancer naive to novel hormonal agents (NHA).

[0143] In some embodiments, the prostate cancer is metastatic prostate cancer naive to novel hormonal agents (NHA).

[0144] In some embodiments, the prostate cancer is castrate-resistant prostate cancer naive to novel hormonal agents (NHA). 1

[0145] In some embodiments, the prostate cancer is castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

[0146] In some embodiments, the prostate cancer is metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA).

[0147] In some embodiments, the prostate cancer is metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

[0148] In some embodiments, the prostate cancer is not prostate cancer naive to novel hormonal agents (NHA). In some embodiments, the prostate cancer that is not prostate cancer naive to novel hormonal agents (NHA) is also metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, or metastatic castrate- sensitive prostate cancer.

[0149] In some embodiments, the subject has a histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate.

[0150] In some embodiments, the subject suffering from prostate cancer (e.g., mCRPC) is also undergoing ongoing androgen deprivation therapy (ADT). In some embodiments, ADT comprises the administration of a gonadotropin releasing hormone analog or inhibitor to the subject. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is leuprolide, goserelin, triptorelin, histrelin, leuprolide mesylate, or a pharmaceutically acceptable salt thereof. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is leuprolide. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is leuprolide mesylate. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is goserelin. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is goserelin acetate. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is triptorelin. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is triptorelin acetate. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is triptorelin pamoate. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is histrelin. In some embodiments, the gonadotropin releasing hormone analog or inhibitor is histrelin acetate. In some embodiments, the subject has undergone an orchiectomy.

[0151] In some embodiments, prior to the administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, the subject experienced progression of prostate cancer on at least one prior approved systemic therapy for metastatic prostate cancer.In some embodiments, prior to the administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, the subject experienced progression of prostate cancer on at least two prior approved systemic therapies for metastatic prostate cancer. In some embodiments, at least one of the prior approved systemic therapies for metastatic prostate cancer is a second-generation androgen inhibitor. In some embodiments, prior to the administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, the subject experienced progression of prostate cancer on at least two prior approved systemic therapies for metastatic prostate cancer, at least one of which is a second-generation androgen inhibitor. In some embodiments, the second-generation androgen inhibitor is abiraterone, abiraterone acetate, enzalutamide, darolutamide, apalutamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the second-generation androgen inhibitor is abiraterone. In some embodiments, the second-generation androgen inhibitor is abiraterone acetate. In some embodiments, the second- generation androgen inhibitor is enzalutamide. In some embodiments, the second-generation androgen inhibitor is darolutamide. In some embodiments, the second-generation androgen inhibitor is apalutamide.

[0152] In some embodiments, prior to the administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, the subject received at least one but not more than three prior second-generation anti-androgen agents (e.g., enzalutamide, abiraterone acetate, abiraterone, darolutamide, or apalutamide). In some embodiments, the subject received one prior second-generation anti-androgen agent. In some embodiments, the subject received two prior second-generation anti-androgen agents. In some embodiments, the subject received three prior second-generation anti-androgen agents.

[0153] In some embodiments, prior to the administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, the subject received no more than two prior chemotherapy regimens. In some embodiments, the subject received two prior chemotherapy regimens. In some embodiments, the subject received one prior chemotherapy regimen. In some embodiments, the subject has not received a prior chemotherapy regimen.

[0154] In some embodiments, the subject has not previously undergone radiation therapy within four weeks prior to the initial the administration of a compound of the present disclosure.

[0155] In some embodiments, the subject has not previously undergone radiation therapy where greater than about 25% of the patient’s bone marrow was irradiated.

[0156] In some embodiments, the subject has not been administered an investigational drug within four weeks prior to the initial the administration of a compound of the present disclosure.

[0157] In some embodiments, the subject has not received a systemic anti-cancer therapy within 2 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure. In some embodiments, the subject has not received a systemic anti-cancer therapy within 2 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure, except for agents to maintain castration status.

[0158] In some embodiments, the subject has not received bicalutamide within 6 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure.

[0159] In some embodiments, the subject has not received mitomycin C within 6 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure.

[0160] In some embodiments, the subject has not received nitrosoureas within 6 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure.

[0161] In some embodiments, the subject has not received abiraterone or abiraterone acetate within 4 weeks of the first administration of the therapeutically effective amount of a bifunctional compound of the present disclosure.

[0162] In some embodiments, the subject has confirmed mCRPC.

[0163] In some embodiments, the subject has received two or more prior systemic therapies, one or more of which was abiraterone or enzalutamide.

[0164] In some embodiments, the subject’s cancer progressed on the most recent therapy.

[0165] In some embodiments, the subject has rising PSA levels (>2 ng / mL) and / or two or more new lesions upon bone scan.

[0166] In some embodiments, the subject suffering from prostate cancer (e.g., mCRPC) will have a different response to treatment with a compound of the disclosure (preferably Compound A) or a pharmaceutically acceptable salt, depending on the AR biomarker status of the subject, i.e., whether the subject has one or more somatic tumor mutations to AR.

[0167] In some embodiments, the subject with prostate cancer comprises at least one somaticAR tumor mutation.

[0168] In some embodiments, the subject with prostate cancer does not comprise the somaticAR tumor mutation of L702X.

[0169] In some embodiments, the subject with prostate cancer does not comprise the somaticAR tumor mutation of L702H.

[0170] In some embodiments, the subject with prostate cancer comprises at least one somatic AR tumor mutation, but does not comprise the somatic AR tumor mutation of L702X.

[0171] In some embodiments, the subject with prostate cancer comprises at least one somatic AR tumor mutation, but does not comprise the somatic AR tumor mutation of L702H.

[0172] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878X.

[0173] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878A.

[0174] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878S.

[0175] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A / D891H.

[0176] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A / S889G.

[0177] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of F877L / T878A.

[0178] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A and H875Y.

[0179] In some embodiments, the subject with prostate cancer comprises two somatic AR tumor mutations of T878A and H875Y.

[0180] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878S and H875Y.

[0181] In some embodiments, the subject with prostate cancer comprises two somatic AR tumor mutations of T878S and H875Y.

[0182] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H875X.

[0183] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H875Y.

[0184] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878X.

[0185] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878A.

[0186] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878A, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0187] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878S.

[0188] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878S, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0189] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of V716X.

[0190] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of V716M.

[0191] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of V716M, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0192] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of W742X.

[0193] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of W742C.

[0194] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of W742C, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0195] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of W742L.

[0196] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of W742L, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0197] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M750X.

[0198] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M750T.

[0199] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M750T, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0200] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M750V.

[0201] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M750V, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0202] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of S889X.

[0203] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of S889G.

[0204] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of S889G, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0205] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of D891X.

[0206] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of D891H.

[0207] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of D891H, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0208] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F876X.

[0209] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F876L.

[0210] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F876L, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0211] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T877X.

[0212] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T877A.

[0213] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T877A, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0214] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F877X.

[0215] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F877L.

[0216] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of F877L, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0217] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H874X.

[0218] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H874Y.

[0219] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H874Y, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0220] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878X, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0221] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878A, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0222] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of T878S, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0223] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M896X.

[0224] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M896V.

[0225] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of M896V, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0226] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A / D891H, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0227] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A / S889G, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0228] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of F877L / T878A, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0229] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878A and H875 Y, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0230] In some embodiments, the subject with prostate cancer comprises two somatic AR tumor mutations of T878A and H875Y, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0231] In some embodiments, the subject with prostate cancer comprises at least the two somatic AR tumor mutations of T878S and H875Y, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0232] In some embodiments, the subject with prostate cancer comprises two somatic AR tumor mutations of T878S and H875Y, and the subject does not comprise the somatic AR tumor mutation of L702H.

[0233] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H875, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0234] In some embodiments, the subject with prostate cancer comprises at least the somatic AR tumor mutation of H875Y, and the subject does not comprise the somatic AR tumor mutation ofL702H.

[0235] In one aspect, treating cancer results in a reduction in size of a tumor. A reduction in size of a tumor may also be referred to as "tumor regression." Preferably, after treatment, tumor size is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Size of a tumor may be measured by any reproducible means of measurement. In a preferred aspect, size of a tumor may be measured as a diameter of the tumor.

[0236] In another aspect, treating cancer results in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by 5% or greater relative to its volume prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Tumor volume may be measured by any reproducible means of measurement.

[0237] In another aspect, treating cancer results in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. Number of tumors may be measured by any reproducible means of measurement. In a preferred aspect, number of tumors may be measured by counting tumors visible to the naked eyeor at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, lOx, or 50x.

[0238] In another aspect, treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. In a preferred aspect, the number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, lOx, or 50x.

[0239] In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active agent or compound of the disclosure. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active agent or compound of the disclosure.

[0240] In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured by calculating for a population the average length of survival following initiation of treatment with an active agent or compound of the disclosure. In another preferred aspect, an increase in averagesurvival time of a population may be measured by calculating for a population the average length of survival following completion of a first round of treatment with Compound A, or a pharmaceutically acceptable salt thereof.

[0241] In another aspect, treating cancer results in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least 5% relative to growth rate prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Tumor growth rate may be measured by any reproducible means of measurement. In a preferred aspect, tumor growth rate is measured according to a change in tumor diameter per unit time.

[0242] In another aspect, treating cancer results in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth may be measured by any reproducible means of measurement. In a preferred aspect, tumor regrowth is measured by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. In another preferred aspect, a decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.

[0243] In some embodiments, the therapeutically effective amount of Compound A is about 10 to about 40 mg, about 20 to about 50 mg, about 30 to about 60 mg, about 40 to about 70 mg, about 50 to about 80 mg, about 60 to about 90 mg, about 70 to about 100 mg, about 80 to about 110 mg, about 90 to about 120 mg, about 100 to about 130 mg, about 110 to about 140 mg, about 120 to about 150 mg, about 130 to about 160 mg, about 140 to about 170 mg, about 150 to about 180 mg, about 160 to about 190 mg, about 170 to about 200 mg, about 180 to about 210 mg, about 190 to about 220 mg, about 200 to about 230 mg, about 210 to about 240 mg, about 220 to about 250 mg, about 230 to about 260 mg, about 240 to about 270 mg, about 250 to about 280 mg, about 260 to about 290 mg, about 270 to about 300 mg, about 280 to about 310 mg, about 290 to about 320 mg, about 300 to about 330 mg, about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to about 390 mg, about 370 to about 400 mg, about 380 to about 410 mg, about 390 to about 420 mg, about400 to about 430 mg, about 410 to about 440 mg, about 420 to about 450 mg, about 430 to about 460 mg, about 440 to about 470 mg, about 450 to about 480 mg, about 460 to about 490 mg, about 470 to about 500 mg, about 480 to about 510 mg, about 490 to about 520 mg, about 500 to about 530 mg, about 510 to about 540 mg, about 520 to about 550 mg, about 530 to about 560 mg, about 540 to about 570 mg, about 550 to about 580 mg, about 560 to about 590 mg, about 570 to about 600 mg, about 580 to about 610 mg, about 590 to about 620 mg, about 600 to about 630 mg, about 610 to about 640 mg, about 620 to about 650 mg, about 630 to about 660 mg, about 640 to about 670 mg, about 650 to about 680 mg, about 660 to about 690 mg, about 670 to about 700 mg, about 680 to about 710 mg, about 690 to about 720 mg, about 700 to about 730 mg, about 710 to about 740 mg, about 720 to about 750 mg, about 730 to about 760 mg, about 740 to about 770 mg, about 750 to about 780 mg, about 760 to about 790 mg, about 770 to about 800 mg, about 780 to about 810 mg, about 790 to about 820 mg, about 800 to about 830 mg, about 810 to about 840 mg, about 820 to about 850 mg, about 830 to about 860 mg, about 840 to about 870 mg, about 850 to about 880 mg, about 860 to about 890 mg, about 870 to about 900 mg, about 880 to about 910 mg, about 890 to about 920 mg, about 900 to about 930 mg, about 910 to about 940 mg, about 920 to about 950 mg, about 930 to about 960 mg, about 940 to about 970 mg, about 950 to about 980 mg, about 960 to about 990 mg, or about 970 to about 1,000 mg administered once, twice, three times, four times, or more daily in single or divided doses (which dose may be adjusted for the patient’s weight in kg, body surface area in m2, and / or age in years).

[0244] In some embodiments, the therapeutically effective amount of Compound A is about 100 mg to about 800 mg.

[0245] In some embodiments, the therapeutically effective amount of Compound A is about 200 mg to about 700 mg.

[0246] In some embodiments, the therapeutically effective amount of Compound A is about 300 mg to about 600 mg.

[0247] In some embodiments, the therapeutically effective amount of Compound A is about 350 mg to about 550 mg.

[0248] In some embodiments, the therapeutically effective amount of Compound A is about 400 mg.

[0249] In some embodiments, the therapeutically effective amount of Compound A is about 420 mg.

[0250] In some embodiments, the therapeutically effective amount of Compound A is 400 mg.

[0251] In some embodiments, the therapeutically effective amount of Compound A is 420 mg.

[0252] In some embodiments, the therapeutically effective amount of Compound A is administered to the subject orally.

[0253] In some embodiments, the therapeutically effective amount of Compound A is administered to the subject once or twice daily.

[0254] In some embodiments, the therapeutically effective amount of Compound A is administered to the subject once daily.

[0255] In some embodiments, the therapeutically effective amount of Compound A is administered to the subject twice daily.EXAMPLES

[0256] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and / or scope of the appended claims.Example 1. Materials and Methods

[0257] Cell lines.

[0258] Vertebral cancer of the prostate (VCaP; Cat#CRL-2876), lymph node carcinoma of the prostate (LNCaP; Cat#CRL-1740), HEK293 (Cat# CRL-1573), MDA PCa 2B (Cat#CRL-2422) and MCF-7 (Cat#HTB-22) cells were purchased from ATCC. T-RexTM-293 cells were purchased from Thermo Fisher (Cat#R71007).

[0259] These cell lines were authenticated using short tandem repeat DNA profiling by the vendors and confirmed approximately every 18 months using the ATCC Cell Line Authentication Service (Cat#135-XV). VCaP, AR-expressing T-RexTM-293, and HEK293 cells were cultured in standard conditions (at 37°C, 5% CO2, 95% humidity) in Dulbecco's Modified Eagle Medium (DMEM; ATCC, Cat#30-2002) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher, Cat#26140095) and 1% penicillin-streptomycin (T-RexTM-293 additionally supplemented with 5pg / mL blasticidin [Invivogen, Cat#ant-bl-l]). LNCaP cells were cultured in RPMI-1640 medium with 10% FBS and 1% penicillin-streptomycin. MDA PCa 2B cells were cultured in HPC-1 media (Athena Cat#ES 0403) with 20% FBS and 1% penicillin-streptomycin on FNC Coating Mix (Athena Cat#ES 0407H) coated plates. MCF-7 cells were cultured in DMEM: F-12 (ATCC, Cat#30-2006) with 10% FBS (at 37°C, 5% CO2, 95% humidity). All cells were regularly tested for absence of mycoplasma contamination.

[0260] To generate AR-expressing T-RexTM-293 cells, cDNAs encoding wild-type AR or clinically relevant mutants were cloned into pcDNATM / 4TO vector (Thermo Fisher, Cat#Vl 02020). The plasmids were transfected into T-RexTM-293 cells, and stable pools were selected using 200 pg / mL zeocin (Thermo Fisher, Cat#R25001) in addition to the 5 ug / mL blasticidin for continued selection for the Tet repressor.

[0261] Western blotting.

[0262] Cells were lysed in radioimmunoprecipitation assay (RIP A) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease (Roche, Cat#l 1697498001) and phosphatase inhibitors (10 mM sodium fluoride, 10 mM P-glycerophosphate, 2 mM sodium orthovanadate, and 10 mM sodium pyrophosphate). Lysates were centrifuged at 15,000 rpm and supernatants were analyzed by SDS-PAGE. Western blotting was performed by transferring samples onto a nitrocellulose membrane, incubating in 5% milk in Tris-buffered saline with Tween 20 at room temperature for 1 hour and probing with the indicated antibody overnight at 4°C. Membranes were visualized using the ECL™ Prime Western blotting detection reagent (GE Healthcare, Cat#RPN2232). (Salami, J. et al. Commun Biol 2018;l :100.)

[0263] AR binding assay.

[0264] Agonist radioligand receptor binding assays were performed using LNCaP cell lysates. Experiments were performed by Eurofins Pharma Discovery Services in France according to the previously published AR assay protocol (Endocrinology 1979;104(4):1007-12).

[0265] AR degradation assay.

[0266] LNCaP and VCaP cells expressing wild-type AR or clinically relevant mutants and MCF-7 cells expressing AR and the glucocorticoid receptor (GR) were treated with Compound A concentrations ranging from 0.03 nM to 3000 nM for 24 hours. AR levels were determined by AR ELISA (Cell Signaling Technology, Cat#12850) without background subtraction.

[0267] Ubiquitination assay.

[0268] VCaP cells cultured in RPMI + 5% charcoal-stripped serum were treated with 2pM carfilzomib in 0.01% dimethyl sulfoxide (DMSO) / starvation media then incubated with Compound A (10 nM) for 2 hours. Cells were lysed in 0.5 mL lx Pierce RIPA buffer (including lx Pierce Protease Inhibitor Cocktail, lOpM PR-619, and 20 pM 1, 10 phenanthroline). Samples (500 pL; normalized using BCA assay [ThermoFisher, Cat#23225]) were incubated with 40 pL TUBE1 (LifeSensors) bead slurry in 50% Tris-buffered saline for 2 hours then centrifuged at 3000 x g, washed, and material eluted from beads using LDS Lysis Buffer and LDS Sample Buffer. Western blotting was performed by transferring samples onto a nitrocellulose membrane, incubating in 5% bovine serum albumin in Tris-buffered saline at room temperature for 1 hour and probing with primary antibody (Cell Signaling Technology, Cat#5153) for 2 days at 4°C followed by horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature. Membranes were visualized using the Clarity substrate (Bio-Rad, Cat#1705061).

[0269] Proteomic screen.

[0270] VCaP cells were treated with Compound A (10 nM, i.e., 10-fold higher than half- maximal degradation concentration [DCso]) for 8 hours. Cell lysates were analyzed by label-free liquid chromatography-tandem mass spectrometry methodology.

[0271] PSA suppression assay.

[0272] LNCaP / AR cells cultured in charcoal-stripped FBS supplemented with 0.1 nM R1881 were treated with Compound A or enzalutamide for 48 hours. Intracellular PSA levels were determined using PSA ELISA (Cell Signaling Technology, Cat#14119).

[0273] Cell proliferation and apoptosis assays.

[0274] VCaP cells were seeded in 96- well plates at 5000 (apoptosis assay) or 20,000 cells (proliferation assay) per well in 150 pL of phenol red-free DMEM + 5% charcoal- stripped FBS (Omega) and incubated at 37°C for 3 days (apoptosis assay) or 4 days (proliferation assay). Cells were treated with 50 pL of 4 x concentrated compound to yield indicated concentrations for each experiment in the presence of 0.1 nM R1881. To measure cell proliferation, treated cells were incubated at 37°C for 6 days, after which CellTiter-Glo® reagent (Promega, Cat#G9242) was added to plates, the plates were shaken for 2 minutes to lyse cells, and then incubated at room temperature for 10 minutes. To measure apoptosis, treated cells were incubated at 37°C for 48 h, after which Caspase-Gio 3 / 7® (Promega, Cat#G8091) was added to plates and incubated at room31temperature for 1 hour. For both assays, plates were read on a luminometer, and data were analyzed and plotted using GraphPad Prism software.

[0275] Animal studies.

[0276] VCaP cells (5x106) were suspended in phenol red-free medium with 75% Matrig el (BD Biosciences, Cat#354234) and were implanted subcutaneously into the dorsal flank of 4- week-old CB17 / severe combined immunodeficiencies (SCID) male mice (Charles River, strain 394). Once tumors were palpable, mice were surgically castrated using an Institutional Animal Care & Use Committee (lACUC)-approved protocol by removing the testes through a scrotal incision under isoflurane anesthesia (induction at 4%, maintenance at 3%); subcutaneous meloxicam 2.5 mg / kg (Boehringer Ingelheim, Cat# NDC 0010-6013-01) was used for analgesia. Following castration, the tumors were allowed to regrow. When the tumors reached approximately 150 mm3, the mice were randomized and dosed with either enzalutamide or Compound A.

[0277] The patient-derived xenograft TM00298 (Jackson Laboratory) was grown in intact male NSG (nonobese diabetic / SCID IL2Ry) mice (The Jackson Laboratory, strain 05557-NSG). Mice were administered once-daily (QD) oral Compound A (10 mg / kg) or enzalutamide (20 mg / kg) for 20 days. Tumor volume was measured twice weekly, and the plasma PSA levels were measured with a PSA ELISA (Sigma, Cat#RAB0331) 16 hours after the last dose.

[0278] Male adult Sprague Dawley rats (Hilltop Lab Animals, Inc. Cat#SD Hla (SD)CVF) were administered QD oral Compound A (5, 15, or 45 mg / kg) or enzalutamide (100 mg / kg) for 10 days, and prostate tissue was isolated and weighed 24 hours after the final dose to assess prostate tissue involution.

[0279] An enzalutamide-resistant tumor model was developed by serial passage of a VCaP xenograft in castrated, enzalutamide-treated (20 mg / kg) CB17 / SCID mice for 2.5 years. Mice bearing enzalutamide-resistant VCaP xenograft tumors were dosed QD with oral Compound A (3 mg / kg or 10 mg / kg) or enzalutamide (20 mg / kg) for 28 days. Tumor volume was measured twice weekly. Tumors were harvested 16 hours after the last dose of Compound A or enzalutamide for Western blot analysis of the indicated proteins.Statistical analysis.

[0280] One-way analysis of variance was used to determine statistically significant differences between the means of the vehicle treated group and the treatment group using GraphPad Prism.Example 2. Radiographic progression-free survival (rPFS) in patients administered Compound A with mCRPC with AR ligand-binding domain (LBD) mutations.

[0281] During a phase 1 / 2 study of Compound A in metastatic castration-resistant prostate cancer (mCRPC), specifically a study of the radiographic progression-free survival (rPFS) in patients administered Compound A with mCRPC with AR ligand-binding domain (LBD) mutations, patients with mCRPC and mutations in AR LBD (Androgen Receptor ligand binding domain, i.e.: amino acids 671-920) have poor prognosis. Compound A showed clinical activity in previously treated patients with mCRPC in a phase 1 / 2 study (Clinical Trial Registration: NCT03888612, incorporated by reference herein in its entirety for all purposes), with enhanced activity seen in patients with the AR LBD mutations T878 and / or H875.Methods.

[0282] In phase 1, patients with mCRPC and 2 or more prior therapies (including a novel hormonal agent [NHA]) received Compound A 35-700 mg once daily (QD) or 210-420 mg twice daily. In phase 2, patients with mCRPC and 1-2 prior NHAs ± prior chemotherapy were assigned to biomarker-defined subgroups. Patients who had one prior NHA or no prior chemotherapy were enrolled in a clinically defined subgroup. All phase 2 patients received 420 mg Compound A once daily. In exploratory analyses across the phase 1 / 2 population treated with 420 mg Compound A QD, efficacy was assessed in patients with AR 878 / 875 mutation(s) without an AR L702 mutation (AR 878 / 875 patients) and in those with any AR LBD missense mutation except AR L702H alone (AR LBD patients).Results

[0283] The median rPFS (95% CI) per prostate cancer working group 3 (PCWG3) criteria was 11.1 months in 25 AR 878 / 875 patients and 8.1 months in 44 AR LBD patients. Best prostatespecific antigen (PSA) declines of > 50% after > 1 month of PSA follow-up were seen in 56.0% of AR 878 / 875 patients (n=25) and 37.2% of AR LBD patients (n=43). In response-evaluable patients with measurable disease at baseline, overall response rate was 9.1% in AR 878 / 875 patients (n=l l) and 10.0% in AR LBD (n=20) patients; 55% and 50%, respectively, had stable disease.

[0284] These data show that Compound A had efficacy in post-NHA patients with mCRPC andAR 878 / 875 or any AR missense LBD mutation (excluding AR L702H alone) and was tolerable.Example 3. Compound A selectively targets wild-type AR and clinically relevant mutants

[0285] The selectivity of Compound A was examined by assessing whether Compound A induced degradation of the glucocorticoid receptor (GR), another nuclear hormone receptor that is closely related to AR. In the MCF-7 breast cancer cell line, Compound A treatment (30 nM, 100 nM, 300 nM) resulted in the degradation of AR, but not GR (FIG. 1A). In addition, an unbiased proteomic screen of nearly 4000 detectable proteins in VCaP cells showed that treatment with 10 nM Compound A for 8 hours led to degradation of only AR when a filter of >2 x degradation and a P value of <0.05 were applied (FIG. IB).

[0286] Since specific point mutations in the AR LBD have been shown to confer resistance to existing prostate cancer therapies (Azad, A. etal. Clin Cancer Res 2015;21(10):2315-24; Romanel, A. et al. Sci Transl Med 2015;7(312):312rel0; Lallous, N. et al. Genome Biol 2016; 17: 10; Wyatt, A. et al. JAMA Oncol 2016;2(12): 1598-606; Jernberg, E. et al. Endocr Connect 2017;6(8):R146- R61), clinically relevant mutants that were stably expressed in T-Rex™-293 cells were tested to determine if those mutants were susceptible to degradation by Compound A. Four of the 6 AR mutant proteins tested (F877L, T878A, M896V, and H875Y) were degraded with similar potency as wild-type AR (FIG. 1C), whereas L702H and the T878A / L702H double mutant were degraded at lesser potency in HEK293 and MDA PCa 2B cells (FIG. ID).

[0287] Other AR mutant proteins tested (F876L, T877A, and H874Y) were also degraded with similar potency as wild-type AR (FIG. IE).

[0288] To further evaluate the range of clinically identified AR mutants that Compound A can degrade, an additional 9 AR single mutants and 4 double mutants were tested.PROCEDURE

[0289] Cell Culturing. Cells were cultured in Growth Media and incubated at 37°C. For the degradation assay, cells were plated (20,000 / well) 200 pL / well in starvation media (DMEM (phenol-red free) + 1% penstrep + 5% CSS) + 0.1 pg / ml tetracycline into a 96 well plate. The cells were incubated in starvation media for 72 hours.

[0290] Compound preparation and dosing. A stock solution of Compound A (10 mM in DMSO) was diluted lOx (5 pL + 45 pL DMSO) in an Eppendorf tube. The drugs were then further diluted lOx (5 pL + 45 pL DMSO) to 100 pM into Column 11 of a 96 well polypropylene plate (“DMSO plate”). Compound A was then serially diluted % log from column 10 to column 3. Use of the outer wells was avoided due to evaporation. 10 pL from DMSO plate was thentransferred into 990 pL of starvation media on the “CSS plate” and mixed to give a 1 pM top concentration. 22.2 pL was transferred from CSS plate to the corresponding plate(s) containing cells. The final compound concentrations are 100 nM (top dose) in Column 11 to 10 pM in Column 3. Column 2 acts as a DMSO control, with a final concentration of 0.1% DMSO. Plates were incubated for 24 hours.

[0291] Cell Lysis and ELISA plating. Media was aspirated off and wells were washed with 100 pL lx DPBS. DPBS was aspirated off and 75 pL lx cell lysis buffer was added directly to each well. Plates were then placed in deli fridge shaker for 5 min at speed 4. Filtration plates were pre- wet with 100 pL lx DPBS. The lysates were then cleared with the filtration plates by spinning down at 3000x rpm for 3 minutes over a new polypropylene collection plate. Lysates were quantified by BCA assay (Thermo Fisher) and stored at -80°C.

[0292] The lysates were then normalized to 25 pg / ml using cell lysis buffer and mixed with ELISA sample diluent to a final volume of 125 pl on AR ELISA plates. Plates were stored at 4°C overnight on cold room shaker speed 5 (gentle swirl).

[0293] ELISA. Plates were incubated at 37°C for 30 min. Mouse AR antibody, anti-mouse antibody, TMB, and STOP solution were allowed to come to room temperature, lx ELISA buffer was loaded in reservoir and the plate washer was primed. The plates were then washed 4 times with 200 uL ELISA buffer. 100 pL / well mouse AR detection Ab was then added to each well and the plates were covered and incubated at 37°C for Ihr. The plates were then washed 4 times with 200uL ELISA buffer. 100 pL / well anti-mouse - HRP conjugated Ab was then added to each well and the plates were covered and incubated at 37°C for 30 min. The plates were then washed 4x with 200uL ELISA buffer. 100 pL of TMB was added and the plates incubated on shaker for 3 min. 100 pL of stop solution was then added once substrate turned blue. Plates were then mixed by incubating on shaker for 3 min and then read at 450 nM and 562 nM (for background subtraction) using a BioTek Synergy HT plate reader.

[0294] Western Blot. A master mix of NuPage 4x LDS sample buffer and 50x sample reducing agent (Invitrogen / Thermo Fisher) was prepared. 21 pL of master mix and 39 pL of lysate was mixed in a PCR plate. Lysates were then normalized using lx LDS + RA (Master mix + lx cell lysis buffer). PCR plate was heated to 95°C for 5 minutes on a heat block, pulsed down in a table centrifuge, mixed, then 1.5 pg was loaded onto a NuPAGE™ 4 to 12%, 26- well gel. Gel box was placed on ice and run at 100V for 5 minutes to allow samples to enter gel, then150V for 1 hour and 15 minutes. The gel was transferred to a Trans-Blot Turbo Midi 0.2 gm Nitrocellulose blot (Bio-Rad) using the Trans-Blot Turbo Transfer system. Blots were placed in 25 mL of TBST 5% milk for 1 hr at room temperature on a shaker to block. Blots were cut once in between 75 kD and 50 kD, separated into different containers, then loaded with primary antibody - Androgen Receptor and GAPDH (Cell Signalling) - at 1 : 1000 in 20 mL TBST 5% milk. Blots were put at 4°C shaking overnight. The following day blots were washed 3 times for 5 minutes each with lx TBST. Blots were incubated in 1 :10,000 secondary antibody - anti-rabbit IgG HRP- in 20 mL TBST 5% milk for 1 hour shaking at room temperature. Blots were washed 3 times for 5 minutes each with lx TBST, then developed using SuperSignal West Femto Reagent (Thermo Fisher). Blots were imaged on the Bio-Rad ChemiDoc using Optimal Chemi and Colorimetric settings.

[0295] Data analysis. Absorbance values were normalized by background subtraction of T- Rex™-293 control cell values. A relative standard curve was then generated in each experiment by serial dilution of ARL702H lysate. Samples were then fit to this curve and relative AR values were determined. The percent AR values were then calculated by comparing to the average DMSO value for each mutant cell pool. Degradation curves were then plotted in a four- parameter logistic (4PL) sigmoidal non-linear fit using GraphPad PRISM. DC50 values were calculated using Nonlin Fit. Western blots were analyzed and bands were quantified through densitometry analysis in Bio-Rad ImageLab software. Androgen receptor band intensity was normalized to corresponding GAPDH bands. The percent AR values were then determined by comparing to the DMSO values for each mutant cell pool, and degradation curves were plotted utilizing the same method listed above.

[0296] AR degradation was characterized by enzyme-linked immunosorbent assay (ELISA) for all AR variants except AR D891H which was characterized by Western Blot. Compound A half-maximal degradation concentration (DCso) data are shown in Figures 6A-6F and are summarized in Table 1 below. All mutants except the L702H mutant were degraded with similar efficiency as wild-type (WT) AR (Table 1). Computational protein modeling studies suggest that the L702H mutation prevents the binding of Compound A and therefore would not be expected to be degraded following Compound A treatment.

[0297] Table 1. Compound A half-maximal degradation concentrations for wild- type and clinically relevant mutant AR expressed in T-Rex™-293 cell lines.SEM = standard error of mean; N = number of independent replicates.

[0298] Notably, Compound A degraded all tested AR LBD mutants that are associated with resistance to abiraterone (Azad, A. et al. Clin Cancer Res 2015;21(10):2315-24, Romanel, A. et al. Sci Transl Med 2015;7(312):312rel0) and / or enzalutamide (Lallous, N. et al. Genome Biol 2016; 17: 10; Wyatt, A. etal. JAMA <9«co / 2016;2(l 2): 1598-606; Jernberg, E. etal. Endocr Connect 2017;6(8):R146-R61) to a similar degree as wild-type AR with the exception of L702H and T878A / L702H which were degraded, but with lesser potency. Without being bound by theory, these data suggest that Compound A may be a potential treatment option for patients whose tumors have developed resistance to NHAs.Example 4. Degradation and Inhibition of the activity of the L702H mutant form of the androgen receptor (AR) with Compound A.

[0299] Two experimental systems were utilized to test the ability of Compound A to degrade AR and inhibit AR L702H activation. The first utilized HEK-293 cells that had been stably transduced with a lentivirus encoding an AR response element (“ARE”) in the promoter region upstream of a luciferase reporter gene (HEK-293 ARE-luciferase reporter cells) and subsequently stably transfected with plasmids expressing either wild-type AR or the AR L702H mutant under the control of a doxycycline-inducible promoter. Stable pools of these reporter cell lines were used to assess with the effects of Compound A or the NHAs enzalutamide and darolutamide on steroid activated AR transcriptional activation, as well as AR degradation by Compound A. The second in vitro system was the prostate cancer cell line MDA PCa 2B which was established from a bone metastasis of a CRPC patient (Navone et al, 1997). This cell line harbors both AR T878A and L702H mutations and has previously been demonstrated to exhibit glucocorticoid responsiveness (Zhao et al, 2000). MDA PCa 2B cells were used to evaluate the functional consequences of Compound A or AR antagonist inhibition of steroid activated proliferation and AR degradation. An extended dose range (up to 10 pM) was utilized in these studies.

[0300] 4.1. Compound A inhibitory activity against steroid activation of AR L702H in HEK-293 ARE-luciferase reporter cells

[0301] 4.1.1 Activation of wild-type AR and AR L702H by steroids

[0302] Wild-type AR or AR L702H HEK-293 ARE-luciferase reporter cell pools were steroid starved for 72 hours using charcoal-stripped serum and then treated with the synthetic androgen R1881, estradiol, progesterone, prednisolone, cortisol, cortisone, or dexamethasone for 24 hours and luciferase activity was measured (FIG. 7A and FIG. 7B).

[0303] Wild-type AR was activated by R1881 and estradiol but none of the other steroids tested (FIG. 7A). AR L702H was activated by R1881, estradiol and all the glucocorticoids tested (prednisolone, cortisol, cortisone) except dexamethasone (FIG. 7B). Neither wild-type AR nor AR L702H were activated by progesterone (FIG. 7A and FIG. 7B). This pattern of L702H activation, including activation by cortisol and cortisone at concentrations within the circulating concentration ranges observed in CRPC patients, is consistent with the published literature (Snaterse et al, Prostate Cancer Prostatic Dis. 2022 Jan 19). Taken together, these data confirm that glucocorticoids activate AR L702H, but not wild type AR.

[0304] The circulating concentration range (CRPC range) refers to concentration range of progesterone, cortisol and cortisone in CRPC patients.

[0305] 4.1.2. Inhibition of wild-type AR and AR L702H activation by Compound A, enzalutamide and darolutamide

[0306] The effect of Compound A, enzalutamide, and darolutamide on activation of wild-type AR and AR L702H was assessed in the HEK-293 ARE-luciferase reporter cells. The cells were steroid starved for 72 hours using charcoal-stripped serum and then treated with the synthetic androgen R1881 (wild-type AR, AR L702H) or the glucocorticoids prednisolone, cortisol, or cortisone (AR L702H) in the absence or presence of the individual AR-targeting agents.

[0307] Compound A inhibited activation of wild-type AR with 0.1 nM R1881 more potently than enzalutamide or darolutamide (Table 2, FIG. 8A).

[0308] Compound A inhibited AR L702H activation by R1881 (1 nM) (Table 2, FIG. 8B) and all glucocorticoids tested (Table 2, FIG. 8C-G), although the activity was less than that observed against wild-type AR. Compound A inhibited the activity of AR L702H more potently than enzalutamide or darolutamide under all conditions tested (Table 2, FIG. 8C-G).

[0309] Table 2. Compound A, enzalutamide, and darolutamide half-maximal effective concentrations (EC50) for inhibition of wildtype AR and AR L702H in HEK-293 ARE-luciferase reporter cellsSEM = standard error of mean; N = number of independent replicates.

[0310] 4.1.3. Degradation of wild-type AR and the AR L702H mutant by Compound A inHEK-293 ARE-luciferase reporter cells

[0311] To assess the effect of Compound A on degradation of wild-type AR and AR L702H, HEK-293 ARE-luciferase reporter cells were steroid starved for 72 hours using charcoal-stripped serum, treated for 24 hours with Compound A and then analyzed by Western blot.

[0312] Compound A treatment induced degradation of both wild-type AR and AR L702H in HEK-293 ARE-luciferase reporter cells (FIG. 9). Wild-type AR was degraded with a half maximal degradation concentration (DCso) of 4.6 nM ± 3.6 nM and a maximum degradation (Dmax) of 96.5% ± 3.1% (n=3 independent experiments) . AR L702H was degraded with a DCso of 101.6 ± 27.4 nM and a Dmax of 82.1% ± 1.4% (n=3 independent experiments).

[0313] 4.2. Compound A inhibitory activity against AR T878A L702H in MDA PCa 2B prostate cancer cells

[0314] 4.2.1. Steroid induced proliferation of MDA PCa 2B cells

[0315] The MDA PCa 2B cell line was established from a bone metastasis of a CRPC patient (Navone et al, Clin Cancer Res. 1997 Dec; 3(12 Pt l):2493-500). This cell line harbors both AR T878A and L702H mutations and has previously been demonstrated to exhibit glucocorticoid responsiveness (Zhao et al, Nat Med. 2000 Jun;6(6):703-6). To confirm the steroid responsiveness, MDA PCa 2B cells were steroid starved for 72 hours using charcoal-stripped serum and then treated with a range of concentrations of the synthetic androgen R1881, cortisol, cortisone, prednisolone, or dexamethasone for 144 hours. Cell number was then assessed. R1881, cortisol, cortisone, prednisolone, and dexamethasone all induced proliferation of the cells compared to control at 144 hours and the viable cell signal at day 0 (FIG. 10). This pattern of responsiveness is consistent with that reported in published literature for AR T878A / L702H activation (Snaterse et al, Prostate Cancer Prostatic Dis. 2022 Jan 19; PMID:35046557).

[0316] 4.2.2. Antiproliferative activity of Compound A, enzalutamide, and darolutamide inMDA PCa 2B cells

[0317] MDA PCa 2B cells were starved for 72 hours using charcoal-stripped serum, and growth was induced by R1881, cortisol, or cortisone in the presence of Compound A, enzalutamide, or darolutamide. After 144 hours, viable cell number was assessed and mean half- maximal effective concentration (ECso) were determined for each drug. Compound Ademonstrated enhanced anti-proliferation potency compared to enzalutamide and darolutamide across all the steroids tested (Table 3, FIG. 11 A-l 1C).

[0318] Table 3. Compound A half-maximal effective concentrations (ECso) for inhibition of MDA PCa 2B prostate cancer cell proliferation.*n=2 **n=4

[0319] 4.2.3. Degradation of the AR T878A / L702H double mutant in MDA PCa 2B cells byCompound A

[0320] To assess the effect of Compound A on degradation of the AR T878A / L702H double mutant, MDA PCa 2B cells were steroid starved for 72 hours using charcoal-stripped serum, treated with Compound A for 24 hours, and then analyzed by western blot. Compound A treatment induced degradation of AR T878A / L702H in MDA PCa 2B cells (FIG. 12). AR T878A L702H was degraded with a DCso of 140 ± 7 nM and a Dmax of 66% ± 2.2% (n=3 independent experiments).

[0321] Assay Description:

[0322] Description of HEK-293 ARE-luciferase reporter cell lines• An AR responsive luciferase reporter HEK-293 cell line pool was generated by infecting the cells with a lentivirus encoding 4 copies of the androgen response element upstream of a minimal CMV promoter and luciferase reporter gene (LVP914-N, GeneTarget Inc).• Stable pools of the HEK-293 ARE-luciferase reporter cell line were selected with GeneticinTM.• Inducible wild-type AR and AR L702H cDNA overexpression constructs were generated at Genewiz (sequences and validation reports detailed in NBK0093-4).HEK-293 ARE-luciferase reporter cells stably expressing inducible wild-type AR or AR L702H were generated via transfection and selected with GeneticinTM and puromycin.

[0323] Media Preparation

[0324] Growth Media:• HEK-293 : DMEM (ATCC) + 10% FBS (Gibco / Thermo Fisher) +1 % Pen-Strep (Gibco / Thermo Fisher)• MDA PCa 2B: HPC-1 (Fisher Scientific) + 20% FBS (Gibco / Thermo Fisher) + 1% Pen- Strep (Gibco / Thermo Fisher) (culture flasks pre-coated with 5mL FNC Coating Mix (Fisher Scientific)

[0325] Starvation Media:• HEK-293: DMEM, high glucose, HEPES, no phenol red (Gibco / Thermo Fisher) + 5% Charcoal Stripped FBS (Omega) + 1% Pen-Strep (Gibco / Thermo Fisher)• MDA PCa2B: RPMI, no phenol red (Gibco / Thermo Fisher) + 5% Charcoal Stripped FBS (Omega) + 1% Pen- Strep

[0326] Procedure

[0327] Cell Culturing: Cells were cultured in Growth Media and incubated at 37°C.

[0328] HEK-293 ARE-luciferase reporter cell degradation assays

[0329] For the HEK-293 ARE-luciferase reporter cell degradation assay, cells were plated (20,000 / well) 100 pL / well in starvation media (DMEM (phenol-red free) + 1% Pen-Strep + 5% CSS) + 5 ng / mL doxycycline into a 96 well plate. The cells were incubated in starvation media for 72 hours. A stock solution of Compound A (lOmM in 100% DMSO) was diluted lOOx (4pL lOmM stock into 400 pL charcoal-stripped RPMI) to 100 pM into column 1 of a 96-deep well polypropylene block.

[0330] Compound A was then serially diluted 4-fold from column 1 to column 10 (Charcoal stripped DMEM + 1% DMSO). Columns 11 and 12 contain CSS DMEM + 1% DMSO. 11.1 pL of drug / media or DMSO / media from deep well block was added to corresponding well in the 96- well plate of HEK-293 ARE-luciferase reporter cells. Final top concentration was lOpM Compound A, and final DMSO concentration in all wells was 0.1%. Cells were incubated with drug for 24 hours.

[0331] HEK-293 ARE-luciferase reporter cell luciferase assays

[0332] Cells were plated (20,000 / well) 100 pL / well in starvation media (DMEM (phenol-red free) + 1% Pen-Strep + 5% CSS) + 5 ng / mL doxycycline into a 96 well plate. The cells were incubated in starvation media for 72 hours.

[0333] For combination dosing: lOx steroid dilutions (1 nM R1881, 10nM R1881; IpM prednisolone, 5 pM prednisolone, 1 pM cortisone; 5 pM cortisone, 1 pM cortisol) were each prepared in 40mL CSS DMEM. A stock solution of Compound A was diluted lOOx (4 pL 3mM + 400 pL each lOx steroid in CSS DMEM) to 30pM (lOx final) in column 1 of a 96-deep wellpolypropylene block. Enzalutamide and darolutamide stock solutions were diluted lOOx (4pL 50mM + 400pL each lOx steroid in CSS DMEM) to 500pM (lOx final) in column 1 of a 96-deep well polypropylene block. Compound A, enzalutamide and darolutamide were then serially diluted 4-fold from column 1 to column 10 in CSS DMEM + 1% DMSO. Columns 11 and 12 contain lOx steroid in CSS DMEM + 1% DMSO. Final DMSO concentration in all wells was 0.1%. 11.1 pL of lOx drug solutions were added to 3 rows of corresponding plate(s) containing cells. Plates were then incubated for 24 hours, and luciferase was measured with Bright-Glo™ Assay (Promega Corp).

[0334] For single steroid dosing: A 10mM R1881 stock solution was diluted lOOx (1 pL + 99 pL DMSO) to 100 pM and then the 100 pM was further diluted 10X (10 pL + 90 pL DMSO) to 10 pM. The 10 pM was diluted lOOx (4 pL + 400 pL CSS DMEM) to lOOnM (lOx final) in column 1 of a 96-deep well polypropylene block. lOOmM stock solutions of prednisolone, estradiol, cortisol, dexamethasone and cortisone were diluted lOx (10 pL + 90 pL DMSO) to lOmM and progesterone was diluted to 1 mM. The solutions of the five steroids were diluted lOOx (4 pL + 400 pL CSS RPMI) to lOOpM or 10 pM (lOx final) in column 1 of 4 subsequent rows of a 96-deep well polypropylene block. The steroids in column 1 were then serially diluted in ’ / 2log steps from column 1 to column 10. Columns 11 and 21 contain CSS DMEM / 1% DMSO.

[0335] 11.1 pL of lOx drug solutions were added to 3 rows of corresponding plate(s) containing cells. Plates were then incubated for 24 hours, and luciferase was measured with Bright-GloTM Assay (Promega Corp).

[0336] MDA PCa 2B degradation assays

[0337] For the MDA PCa 2B degradation assay, cells were plated (500,000 / well) ImL / FNC- precoated well in growth media (HPC-1 + 20% FBS + 1% Pen-Strep) into a 12 well plate. The cells were incubated for 24 hours to maximize cell adherence. The media was then changed to starvation media (RPMI (phenol-red free) + 1% Pen-Strep + 5% CSS) and cells were further incubated for 48 hours. A stock solution of Compound A (lOmM in 100% DMSO) was diluted lOOx (4pL lOmM stock into 400pL charcoal- stripped RPMI) to 100 pM into column 1 of a 96- deep well polypropylene block. Compound A was then serially diluted 4-fold from column 1 to column10 (Charcoal stripped RPMI + 1% DMSO). Columns 11 and 12 contain CSS RPMI + 1% DMSO.110 pL of drug / media or DMSO / media from deep well block was added to corresponding well in the 12-well plate of MDAPCa2B cells. Final top concentration was lOpM Compound A, and final DMSO concentration in all wells was 0.1%. Cells were incubated with drug for 24 hours.

[0338] MDA PCa 2B cell viability assays

[0339] For the MDAPCa2B cell viability assays, cells were plated (60,000 / well) 200 pL / well in starvation media (RPMI (phenol-red free) + 1% Pen-Strep + 5% CSS) into a 96-well plate and incubated in starvation media for 72 hours.

[0340] For combination dosing: lOx steroid dilutions (lOnM Rl 881; 1 pM cortisone; 1 pM cortisol; 5pM cortisol; 1 pM prednisolone) were each prepared in 40mL CSS RPMI. A stock solution of Compound A was diluted 300x (1.3 pL lOmM + 400 pL each lOx steroid in CSS RPMI) to 30pM (lOx final) in column 1 of a 96-deep well polypropylene block. Enzalutamide and darolutamide stock solutions were diluted 200x (2pL lOOmM + 400pL each lOx steroid in CSS RPMI) to 500pM (lOx final) in column 1 of a 96-deep well polypropylene block.Compound A, enzalutamide and darolutamide were then serially diluted 4-fold from column 1 to column 10. Columns 11 and 12 contain lOx steroid in CSS RPMI.

[0341] For single steroid dosing: A 10mM R1881 stock solution was diluted lOOx (1 pL + 99 pL DMSO) to 100 pM and then the 100 pM was further diluted 10X (10 pL + 90 pL DMSO) to 10 pM. The 10 pM was diluted lOOx (4 pL + 400 pL CSS RPMI) to lOOnM (lOx final) in column 1 of a 96-deep well polypropylene block. lOOmM stock solutions of prednisolone, cortisol, dexamethasone and cortisone were diluted lOx (10 pL + 90 pL DMSO) to lOmM. The lOmM solutions of the four corticosteroids were diluted lOOx (4 pL + 400 pL CSS RPMI) to lOOpM (lOx final) in column 1 of 4 subsequent rows of a 96-deep well polypropylene block. The 100nM R1881 and lOOpM corticosteroids in column 1 were then serially diluted in ’ / 2log steps from column 1 to column 10. Columns 11 and 21 contain CSS RPMI / 1% DMSO.

[0342] 22.2pL of lOx drug solutions were added to 3 rows of corresponding plate(s) containing cells. Plates were then incubated for 6 days, and viability was measured using CellTiter-Glo® 2.0 Assay (Promega Corp).Example 5. Phase 1 / 2 Study of Compound A in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Radiographic progression-free Survival in Patients with Androgen Receptor Ligand- Binding Domain Mutations

[0343] The clinical activity of Compound A in patients with mCRPC was evaluated in patients having tumors harboring any AR ligand-binding domain (LBD) missense mutation except AR L702H alone (“AR LBD patients”). Compound A was also evaluated in a subgroup of AR LBD patients with AR T878 and / or H875 mutations without an AR L702H mutation (“AR 878 / 875 patients”).Methods.

[0344] In phase 1, patients with mCRPC received Compound A 35-700 mg once daily (QD) or 210-420 mg twice daily. In phase 2, patients with mCRPC were assigned to subgroups based on AR mutation status or a clinically defined subgroup (patients who had 1 prior novel hormonal agent (NHA) and no prior chemotherapy) and received Compound A 420 mg QD.

[0345] Key eligibility criteria: confirmed mCRPC and disease progression on last line of treatment. Specifically, for phase 1 dose escalation: disease progression on >2 prior lines of systemic therapy, including abiraterone or enzalutamide. For phase 2 dose expansion: 1-2 prior NHAs with <1 prior chemotherapy regimen each for castration-sensitive PC and CRPC.

[0346] In this study, patients who received Compound A 420 mg QD in either phase 1 or phase 2 were pooled and efficacy was assessed in patients with any AR LBD missense mutation except AR L702H alone (“AR LBD patients”) and the subgroup with AR T878 and / or H875 mutation(s) without an ARL702H mutation (“AR 878 / 875 patients”).Baseline Characteristics

[0347] 153 patients across the phase 1 / 2 study received Compound A 420 mg QD, including45 patients with AR LBD mutations excluding L702H alone, 26 of whom had AR 878 / 875 without L702H (Table 4).

[0348] Table 4. Baseline Characteristics.Efficacy.

[0349] Median radiographic progression-free survival (rPFS) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) was 8.2 months (95% CI: 3.8-NR) in AR LBD patients (20 events in 45 patients) and 11.1 months (95% CI: 7.1-NR) in the AR878 / 875 subgroup (10 events in 26 patients; Fig. 2).

[0350] PSA declines of >50% and >30%, respectively, after >1 month of PSA follow-up were seen in 36.4% and 50.0% of evaluable AR LBD patients (n=44) and in 53.8% and 65.4% of patients in the AR878 / 875 subgroup (n=26; Fig. 3).

[0351] In response-evaluable patients with measurable disease at baseline, overall response rate (ORR) was 10.0% in AR LBD patients (n=20) and 9.1% in the AR 878 / 875 subgroup (n=l l); 55.0% and 54.5%, respectively, had stable disease. 16 (36%) AR LBD patients were on treatment for >24 weeks (7 [16%] for >48 weeks) with 4 ongoing; 11 (42%) AR 878 / 875 patients were on treatment for >24 weeks (6 [23%] for >48 weeks) with 4 ongoing (Fig. 4).

[0352] Safety.

[0353] Across the phase 1 / 2 study, 147 (96%) of 153 patients treated with Compound A 420 mg QD had a treatment-emergent adverse event (TEAE); 47 (31%) had a grade 3 / 4 TEAE. 17 (11%) patients had a dose reduction due to a TEAE and 19 (12%) discontinued treatment due to a TEAE. The most common TRAEs with Compound A 420 mg QD were gastrointestinal symptoms (nausea, vomiting) and fatigue. No grade >4 TRAEs occurred (Table 5).

[0354] Table 5. TRAEs reported in >10% of patients treated with Compound A 420 mg QD in the phase 1 / 2 study (N=153).

[0355] In this post-novel hormonal agent (NHA) mCRPC population, clinical activity for Compound A was observed in patients with tumors harboring missense AR LBD mutations excluding L702H alone (median rPFS: 8.2 months; %PSAso: 36%) including in the subgroup of patients with AR 878 / 875 mutations (median rPFS: 11.1 months; %PSAso: 54% 14 / 26 patients). Moreover, administration of Compound A 420 mg QD was tolerated with manageable side effects.

[0356] The PSAso rates (best PSA declines >50%) in patients with various mutation status is summarized below in Table 6 and in Fig. 5. PSA declines >50% were observed in 54% of patients with an AR 878 / 875 mutation, but without a L702H mutation. In contrast, in patients with an AR878 / 875 mutation and a co-occurring L702H mutation, PSA declines >50% were only observed in 9% patients.

[0357] Table 6. Summary of PS Aso rates by Mutation Status.Example 6. Summary of preliminary clinical activity

[0358] In the Phase 1 dose-escalation portion of the study, participants with mCRPC and at least 2 prior therapies (including at least one NHA) received bavdegalutamide orally at doses ranging from 35 to 700 mg QD or 140 to 420 mg BID. Higher bavdegalutamide exposure was associated with increased frequency of PSA reductions. Earlier data from the Phase 1 doseescalation portion suggested enhanced clinical activity for bavdegalutamide in participants with specific molecular profiles, notably AR T878 / H875 mutations. Participants with tumors harboring AR T878 / H875 mutations, treated at > 420 mg or achieving exposure above the nonclinical minimum efficacious threshold, exhibited enhanced clinical activity. A daily dose of 420 mg was selected for the Phase 2 expansion based on pharmacokinetics, safety, tolerability, and efficacy.

[0359] The ongoing Phase 2 expansion of this study is characterizing bavdegalutamide at 420 mg QD in participants with confirmed mCRPC and disease progression (>2 rising PSA values) on or since their most recent therapy. Participants with 1-2 prior NHAs and at least one prior chemotherapy regimen were enrolled in 1 of 3 biomarker-defined subgroups and a 4th subgroup of less prior therapy (1 prior NHA and no prior chemotherapy). A total of 195 participants (71 in Phase 1 and 124 in Phase 2) were enrolled and had received at least 1 dose of bavdegalutamide.

[0360] A summary of preliminary efficacy across the evaluable Phase 1 / 2 population is described below:

[0361] PSAso and PSA30

[0362] • In all participants across the Phase 1 / 2 biomarker and PSA-evaluable population(n=152; i.e., biomarker-evaluable participants treated at >420 mg QD [Phase 1 and 2] or with exposure above the minimum efficacious threshold in nonclinical xenograft tumor models [Phase 1] and with >4 weeks of PSA follow-up): PSAso rate was 17% and the PSA30 rate was 31%.

[0363] • In the subgroup of participants with tumors harboring AR T878 / H875 mutations(n=28): PSA50 rate was 46% and PSA30 rate was 57%. In 8 participants with AR T878 / H875 mutations and co-occurring AR L702H mutations, PSA50 and PSA30 rates were 0% and 38%, respectively.

[0364] Of the 28 AR T878 / H875-positive participants, 12 (43%) received bavdegalutamide for >24 weeks, including 2 with co-occurring ARL702H mutations, and 9 were ongoing as of the data cutoff date.

[0365] RECIST Responses

[0366] • In phase 1 / 2 participants who were biomarker and Response Evaluation Criteria inSolid Tumors (RECIST)-measurable (n=49) and treated at >420 mg QD (or with exposure above the minimum efficacious threshold in nonclinical xenograft tumor models [Phase 1]), tumor shrinkage was observed in some participants regardless of AR T878 / H875 mutation status.

[0367] Two of the 7 RECIST-Measurable participants with tumors harboring AR T878 / H875 mutations had confirmed RECIST partial responses, 1 of whom is continuing treatment. Three participants had stable disease with tumor shrinkage, 2 of whom are still on treatment.

[0368] Of the 42 RECIST-Measurable participants without AR T878 / H875 mutations: 1 had confirmed RECIST partial response and is continuing treatment; 3 had unconfirmed partial responses, 2 of whom are continuing treatment; and 16 had stable disease, 7 of whom are still on treatment.

[0369] In this study, other clinically relevant AR mutations were also observed in a small subset of patients; however, most of the other mutations co-occurred with the more prevalent mutations such as T878A / S, H875Y, or L702H. Furthermore, this small subset included a heterogenous mix with low frequencies of these specific mutations.

[0370] In the dose escalation portion of the clinical study, 71 participants have been treated in 9 cohorts at bavdegalutamide doses ranging from 35 to 700 mg QD, or 210 to 315 mg BID.

[0371] In the Phase 2 portion of study the clinical study, 124 participants received at least one dose of bavdegalutamide at 420 mg QD. Treatment-emergent adverse events (TEAE) werereported for 111 / 124 (90%) of participants and most were mild to moderate (Grade 1 or Grade 2) in severity. Treatment-related TEAEs were reported for 59 / 124 (48%) participants and no Grade 4 treatment-related TEAEs were reported at 420 mg QD.

[0372] The most common treatment-related TEAEs of any grade at 420 mg QD were nausea (all grades: 48%; Grade 3: 2%), fatigue (all grades: 35%; Grade 3: 1%), vomiting (all grades: 28%; Grade 3: 1%), decreased appetite (all grades: 28%; Grade 3: 1%), diarrhea (all grades: 20%; Grade 3: 2%), and alopecia (all grades: 12%; Grade 3: 1%). The only treatment-related TEAEs leading to discontinuation that were reported for more than 1 participant were nausea (5 / 124; 4%), fatigue (3 / 124; 2%), and vomiting (2 / 124; 2%).

[0373] Preliminary PK results indicated dose dependent increases in Cmax and AUC for the specific enantiomers and total bavdegalutamide on Day 15 or Day 22 (Day 15 or Day 21 time point depending on dose cohort) in each cohort up to 420 mg QD. At the 420 mg daily dose, the time to maximum plasma concentration (Tmax) for total bavdegalutamide was achieved between 4- and 8- hours post-dose on Day 1 with the median Tmax of 6 hours post-dose. Accumulation occurred between Day 1 and Day 15 or Day 21.

[0374] The dose of 420 mg QD more consistently yielded mean steady-state AUC near or above the nonclinical minimum efficacious threshold associated with tumor growth inhibition in the VCaP tumor xenograft mouse model with more patients achieving exposure above the nonclinical minimum efficacious threshold associated with tumor growth inhibition in an enzalutamide resistant VCaP tumor xenograft mouse model.

[0375] • Pharmacodynamics / Pharmacokinetics: bavdegalutamide exposures increased dose proportionally through the 420 mg dose, and 420 mg was the lowest dose that resulted in the highest percentage of patients with AUCo-24,ss values at or above the minimum nonclinical exposure threshold for efficacy based on enzalutamide-resistant xenograft models.

[0376] • Preliminary results with bavdegalutamide have shown clinical activity in participants with mCRPC after 1 to 2 prior NHAs and <1 prior chemotherapy regimen for CSPC and CRPC. Enhanced activity was seen in participants with tumors harboring AR T878 / H875 mutations versus participants with tumors that did not harbor AR T878 / H875 mutations, which appears to represent a bavdegalutamide sensitive population in the post-NHA setting.

[0377] Efficacy: In the Part A portion (Phase 1 dose-escalation) of the study, increases in exposure were associated with increased frequency of PSA reductions. Among the participantswith tumors harboring AR T878X / H875Y mutations treated at >420 mg or achieving exposure above the nonclinical minimum efficacious threshold, 3 / 6 participants achieved a >50% decline in PSA (PSAso). No PSA responses were observed in patients with exposures below the minimum efficacious threshold, including 3 patients whose tumors harbored AR T878 / H875 mutations, or among the 7 PSA evaluable participants treated at 280 mg QD, the dose immediately below the Phase 2 dose. The efficacy signal was further observed in the ongoing Part B among the 22 participants with tumors harboring AR 878 / H875 mutations treated with 420 mg QD, 10 / 22 participants achieved a PSA50. This resulted in an overall PSA50 of 48% in this selected population.EQUIVALENTS

[0378] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

[0379] The methods of the disclosure have been described herein by reference to certain preferred embodiments. However, as particular variations thereon will become apparent to those skilled in the art, based on the disclosure set forth herein, the disclosure is not to be considered as limited thereto.

[0380] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the specification and claims, the singular forms also include the plural unless the context clearly dictates otherwise.

[0381] It is to be understood that at least some of the descriptions of the disclosure have been simplified to focus on elements that are relevant for a clear understanding of the disclosure, while eliminating, for purposes of clarity, other elements that those of ordinary skill in the art will appreciate may also comprise a portion of the disclosure. However, because such elements are well known in the art, and because they do not necessarily facilitate a better understanding of the disclosure, a description of such elements is not provided herein.

[0382] Further, to the extent that a method does not rely on the particular order of steps set forth herein, the particular order of the steps recited in a claim should not be construed as a limitation on that claim.

[0383] All patents, patent applications, references and publications cited herein are fully and completely incorporated by reference as if set forth in their entirety. Such documents are not admitted to be prior art to the present disclosure.ENUMERATED EMBODIMENTS

[0384] The aspects of the present disclosure are further described with reference to the following embodiments:A. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof.B. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,C. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,or a pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration.D. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,, wherein the subject is in a fed state at the time of administration.E. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,or a pharmaceutically acceptable salt thereof.F. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration.G. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,H. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration.I. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof.J. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitiveprostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration.K. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,L. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration.M. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, where the subject with prostate cancer comprises at least one somatic AR tumor mutation.N. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time ofadministration, where the subject with prostate cancer comprises at least one somatic AR tumor mutation.O. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,where the subject with prostate cancer comprises at least one somatic AR tumor mutation.P. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration, where the subject with prostate cancer comprises at least one somatic AR tumor mutation.Q. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.R. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.S. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration, and where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.T. In one aspect, this application pertains to a method of treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration, and where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.U. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, where the subject comprises at least one somatic AR tumor mutation as described herein.V. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancernaive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,or a pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration, and where the subject comprises at least one somatic AR tumor mutation as described herein.W. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,where the subject comprises at least one somatic AR tumor mutation as described herein.X. In one aspect, this application pertains to a method of treating: adenocarcinoma of the prostate, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitiveprostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration, and where the subject comprises at least one somatic AR tumor mutation as described herein.Y. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, where the subject comprises at least one somatic AR tumor mutation as described herein.Z. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration, and where the subject comprises at least one somatic AR tumor mutation as described herein.AA. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,where the subject comprises at least one somatic AR tumor mutation as described herein.BB. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration, and where the subject comprises at least one somatic AR tumor mutation as described herein.CC. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.DD. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,pharmaceutically acceptable salt thereof, wherein the subject is in a fed state at the time of administration, where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.EE. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.FF. In one aspect, this application pertains to a method of treating prostate cancer naive to novel hormonal agents (NHA), metastatic prostate cancer naive to novel hormonal agents (NHA), castrate-resistant prostate cancer naive to novel hormonal agents (NHA), castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), metastatic castrate-resistant prostate cancer naive to novel hormonal agents (NHA), or metastatic castrate-sensitive prostate cancer naive to novel hormonal agents (NHA), in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound A,wherein the subject is in a fed state at the time of administration, where the subject with prostate cancer comprises at least one somatic AR tumor mutation as described herein.

Claims

CLAIMSWhat is claimed is:

1. A method of treating prostate cancer in a subject, comprising administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the subject does not have an AR L702H mutation.

2. A method of selecting a subject for treatment of prostate cancer, comprising:(i) determining the subject’s AR mutation status; and(ii) administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof only if the subject does not have an AR L702H mutation.

3. A method of treating prostate cancer in a subject, comprising administering Compound A:pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein if the subject has an AR L702H mutation the subject is not administered Compound A, or a pharmaceutically acceptable salt thereof.

4. A method of treating prostate cancer in a subject, comprising administering Compound A:need thereof, wherein the subject does not have an AR L702H mutation.

5. A method of selecting a subject for treatment of prostate cancer, comprising:(i) determining the subject’s AR mutation status; and(ii) administering Compound A:need thereof only if the subject does not have an AR L702H mutation.

6. A method of treating prostate cancer in a subject, comprising administering Compound A:need thereof, wherein if the subject has an AR L702H mutation the subject is not administered Compound A.

7. The method of any one of claims 1-6, wherein the prostate cancer is metastatic prostate cancer.

8. The method of any one of claims 1-6, wherein the prostate cancer is castrate-resistant prostate cancer.

9. The method of any one of claims 1-6, wherein the prostate cancer is metastatic castrateresistant prostate cancer.

10. The method of any one of claims 1-6, wherein the prostate cancer is castrate-sensitive prostate cancer.

11. The method of any one of claims 1 -6, wherein the prostate cancer is metastatic castratesensitive prostate cancer.

12. The method of any one of claims 1-6, wherein the prostate cancer is prostate cancer naive to novel hormonal agents (NHA).

13. The method of any one of claims 1-6, wherein the prostate cancer is castrate-sensitive prostate cancer naive to novel hormonal agents (NHA).

14. The method of any one of claims 1-6, wherein the prostate cancer is castrate- resistant prostate cancer naive to novel hormonal agents (NHA).

15. The method of any one of claims 1-6, wherein the prostate cancer is metastatic prostate cancer naive to novel hormonal agents (NHA).

16. The method of any one of claims 1-6, wherein the prostate cancer is metastatic castrateresistant prostate cancer naive to novel hormonal agents (NHA).

17. The method of any one of claims 1-6, wherein the prostate cancer is metastatic castratesensitive prostate cancer naive to novel hormonal agents (NHA).

18. The method of any one of claims 1-17, wherein the subject has any AR LBD mutation except L702H.

19. The method of any one of claims 1-18, wherein the subject has any AR LBD mutation other than T878X and L702H.

20. The method of any one of claims 1-18, wherein the subject has any AR LBD mutation other than H875X and L702H.

21. The method of any one of claims 1-20, wherein the subject has any AR LBD mutation other than T878X, H875X, and L702H.

22. The method of any one of claims 1-18, wherein the subject has an AR missense mutation between codons 677-920, without an ARL702H mutation.

23. The method of any one of claims 1-17 or 22, wherein the subject has an AR T878X mutation without an AR L702H mutation.

24. The method of any one of claims 1-17 or 22, wherein the subject has an AR H875X mutation without an AR L702H mutation.

25. The method of any one of claims 1-17 or 22, wherein the subject has both an AR T878X and a H875X mutation without an AR L702H mutation.

26. The method of any one of claims 1-25, wherein the subject is administered Compound A once daily.

27. The method of any one of claims 1-26, wherein the subject is administered 400 mg Compound A once daily.

28. The method of any one of claims 1-26, wherein the subject is administered 420 mg Compound A once daily.

Citation Information

Patent Citations

  • Compounds and methods for the targeted degradation of androgen receptor

    US10584101B2

  • Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same

    US20230012321A1

  • Methods of treating prostate cancer

    US20220184078A1

  • Methods of treating prostate cancer

    US20230128132A1

  • Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same

    WO2021231174A1

Cited By

  • Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

    US12496301B2